[
    {
        "result": [
            {
                "topic": "Qutenza (Topical Capsaicin 8%)",
                "count": 5,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Neuropathic Pain",
                "count": 5,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "End Stage Renal Failure",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Critical Digital Ischaemia",
                "count": 3,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Topical Capsaicin Patch",
                "count": 4,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Capsaicin Mechanism of Action on TRPV1 receptors",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Postherpetic Neuralgia (PHN)",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Diabetic Peripheral Neuropathy (DPN)",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Clinical Trial NCT01704339",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Visual Analogue Pain Score",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Critical Limb Ischemia (CLI)",
                "count": 3,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Peripheral Arterial Disease",
                "count": 2,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Revascularization Procedures (Angioplasty, Stenting, Bypass)",
                "count": 1,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Pharmacological Agents for CLI (Pentoxifylline, Cilostazol)",
                "count": 1,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Wound Care in CLI (Advanced Dressings, Negative Pressure Therapy)",
                "count": 1,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Lifestyle Modifications for CLI (Smoking Cessation, Diet, Exercise)",
                "count": 1,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Gene Therapy and Stem Cell Therapy in CLI Research",
                "count": 1,
                "cluster": "Peripheral Arterial Disease and Critical Limb Ischemia Management"
            },
            {
                "topic": "Gr\u00fcnenthal GmbH Pharmaceutical Company",
                "count": 4,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Pain Management Portfolio",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Resiniferatoxin (RTX) Phase III Development",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Nociceptin/Orphanin FQ Peptide Receptor (NOP) Agonist Phase I Trial",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Glucocorticoid Receptor Modulator (GRM) Phase I Trial",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal and Kyowa Kirin Joint Venture (Gr\u00fcnenthal Meds)",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Acquisition of Nebido\u2122 for Testosterone Replacement Therapy",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Global Manufacturing Sites",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Recent Mergers and Acquisitions (Thar Pharmaceuticals, Averitas Pharma)",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            }
        ],
        "drug_generic_name": "Capsaicin Topical Patch",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Abatacept",
                "count": 11,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Refractory Dermatomyositis",
                "count": 9,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Dermatomyositis",
                "count": 10,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Rheumatoid Arthritis",
                "count": 5,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Juvenile Idiopathic Arthritis",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Psoriatic Arthritis",
                "count": 4,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Selective Co-Stimulation Modulator",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "CTLA-4 Fusion Protein",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Immunosuppressive Therapy",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Glucocorticoids Dosage",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "IMACS Score Improvement",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Clinical Trial NCT04946669",
                "count": 4,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "The First Affiliated Hospital with Nanjing Medical University",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Wenfeng Tan",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Bristol-Myers Squibb",
                "count": 8,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Orencia",
                "count": 5,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Intravenous Abatacept Infusion",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Subcutaneous Abatacept Injection",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Autoimmune Muscle and Skin Inflammation",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Juvenile Dermatomyositis Treatment",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Adverse Events of Abatacept",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Biologic Disease-Modifying Antirheumatic Drug (DMARD)",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Pro-inflammatory Cytokines in Dermatomyositis",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "International Myositis Assessment and Clinical Studies (IMACS) Score",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Safety and Efficacy in Refractory Dermatomyositis",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Clinical Research Collaboration in China",
                "count": 2,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "FDA Approval for Abatacept",
                "count": 3,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Patent and Exclusivity of Abatacept",
                "count": 1,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Physical Therapy in Dermatomyositis",
                "count": 1,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Intravenous Immunoglobulin (IVIG) Therapy for Dermatomyositis",
                "count": 1,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Plasmapheresis in Severe Dermatomyositis",
                "count": 1,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Bristol-Myers Squibb Neuroscience Acquisitions",
                "count": 2,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "Karuna Therapeutics Acquisition",
                "count": 1,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "RayzeBio Acquisition",
                "count": 1,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "BMS Revenue 2024",
                "count": 1,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "BMS Manufacturing Facilities in New Jersey and California",
                "count": 2,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            }
        ],
        "drug_generic_name": "Abatacept",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Cyclosporine",
                "count": 6,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Etoposide",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Fludarabine Phosphate",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Melphalan",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Mycophenolate Mofetil",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Tacrolimus",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Thiotepa",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 6,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neuroblastoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Rhabdomyosarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Allogeneic Hematopoietic Stem Cell Transplantation",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Pediatric and Adolescent-Young Adult High Risk Solid Tumors",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Hematopoietic Stem Cell Transplantation Conditioning Regimen",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Transplant-related Mortality",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Grade III or Higher Organ Toxicity",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Platelet and Neutrophil Engraftment",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Graft-versus-Host Disease",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Overall Survival Post Stem Cell Transplant",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Stem Cell Transplant Eligibility Criteria",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Immunosuppressant Drug Class",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Calcineurin Inhibition by Cyclosporine",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "EWSR1-WT1 Fusion Gene in DSRCT",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "t(11;22)(p13;q12) Chromosomal Translocation",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Multimodal Therapy for DSRCT",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neoadjuvant Chemotherapy",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Aggressive Surgical Resection for DSRCT",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Radiation Therapy for DSRCT",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Stem Cell Rescue",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "EWSR1-WT1 Fusion Protein Tumorigenesis Mechanism",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Platelet-Derived Growth Factor-A Role in DSRCT",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Sandoz Pharmaceuticals Development of Cyclosporine",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Pharmaceuticals Licensing and Manufacturing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Allergan Licensing and Manufacturing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "AbbVie's Acquisition of Allergan",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ophthalmic Emulsion Formulation of Cyclosporine (Restasis)",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Cyclosporine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Allogeneic Hematopoietic Stem Cell Transplantation",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 6,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Etoposide chemotherapy drug",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Recurrent and Refractory High-Risk Solid Tumors in Pediatrics and Adolescents",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "M.D. Anderson Cancer Center Clinical Research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Tacrolimus immunosuppressant use",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cyclosporine immunosuppressant use",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mycophenolate Mofetil immunosuppressant use",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin in conditioning regimens",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fludarabine Phosphate chemotherapy agent",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Melphalan chemotherapy agent",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Thiotepa chemotherapy agent",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neuroblastoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Rhabdomyosarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Phase II Pediatric Oncology Clinical Trial (NCT04530487)",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Transplant Related Mortality and Organ Toxicity Outcomes",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Graft-versus-host Disease (GVHD) in Stem Cell Transplantation",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Chemotherapy Conditioning Regimens prior to HSCT",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Bristol-Myers Squibb (BMS) Oncology Drug Development",
                "count": 2,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "Emcure Pharmaceuticals Generic Drug Manufacturing",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Etoposide Mechanism of Action via Topoisomerase II Inhibition",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric and Adolescent High-Risk Solid Tumor Treatment Strategies",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Genetic Pathophysiology of Desmoplastic Small Round Cell Tumor (EWSR1-WT1 fusion)",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            }
        ],
        "drug_generic_name": "Etoposide",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Cyclosporine administration IV and PO",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Etoposide intravenous chemotherapy",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Fludarabine Phosphate use in conditioning and hematologic malignancies",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin intravenous use",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Melphalan intravenous chemotherapy",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Mycophenolate Mofetil IV and oral use",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Tacrolimus IV and oral immunosuppression",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Thiotepa intravenous chemotherapy",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor (DSRCT)",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Recurrent and refractory pediatric solid tumors",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neuroblastoma recurrent and refractory",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Rhabdomyosarcoma recurrent and refractory",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk pediatric solid tumors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial NCT04530487 on HSCT in pediatric solid tumors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Transplant-related mortality and organ toxicity monitoring",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Acute and chronic graft-versus-host disease (GVHD) assessment",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Engraftment of platelets and neutrophils post HSCT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric and adolescent patients under 25 years with chemo-responsive solid tumors",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "M.D. Anderson Cancer Center clinical research in pediatric oncology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fludarabine Phosphate drug pharmacology and approvals",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "B-cell chronic lymphocytic leukemia treatment with Fludarabine Phosphate",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label Fludarabine use in lymphodepletion before CAR T-cell therapy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "EWS-WT1 fusion gene in DSRCT pathogenesis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chromosomal translocation t(11;22)(p13;q12) in DSRCT",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Aggressive multimodal therapy for DSRCT including surgery, chemo, radiotherapy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trials exploring targeted therapies and immunotherapy in DSRCT",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Berlex Laboratories, Sanofi, Areva Pharmaceuticals manufacturing Fludarabine Phosphate",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sanofi oncology portfolio and global distribution",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Areva Pharmaceuticals oncology injectables and US-focused manufacturing",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Fludarabine Phosphate",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Cyclosporine administration routes",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Etoposide intravenous administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Fludarabine Phosphate intravenous administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin intravenous administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Melphalan intravenous administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Mycophenolate Mofetil IV and oral administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Tacrolimus intravenous and oral administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Thiotepa intravenous administration",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 6,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Recurrent and refractory solid tumors in pediatric and young adult patients",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Neuroblastoma",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Recurrent and refractory Rhabdomyosarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for high-risk solid tumors",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial NCT04530487",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Hematopoietic stem cell transplantation conditioning regimen",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Transplant-related mortality (TRM) within 30 days",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Grade III or higher organ toxicity attributable to conditioning",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Platelet and neutrophil engraftment times post-transplant",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Acute and chronic graft-versus-host disease (GVHD) incidence",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Overall survival rates post-HSCT at 100 days and 1 year",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for HSCT in refractory solid tumors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rabbit Anti-Human Thymocyte Globulin (rATG) / Thymoglobulin\u00ae",
                "count": 7,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Immunosuppressant polyclonal antibody in transplantation",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Mechanism of action of rATG targeting T-lymphocytes",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Prevention and treatment of acute rejection in organ transplantation",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Off-label use of rATG for graft-versus-host disease management",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "rATG dosage and survival outcomes in hematopoietic stem cell transplant patients",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Sanofi Genzyme as manufacturer of Thymoglobulin\u00ae",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor (DSRCT) molecular pathogenesis and EWSR1-WT1 fusion gene",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "DSRCT epidemiology: pediatric and young adult predominance with male bias",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Multimodal treatment approaches for DSRCT including chemotherapy, surgery, radiation, and stem cell rescue",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Research on targeted therapies and immunotherapies for DSRCT",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Sanofi Genzyme company profile and focus on rare diseases and immunology",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Sanofi's acquisition of Genzyme to enhance biotechnology and specialty care portfolio",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            }
        ],
        "drug_generic_name": "Rabbit Anti-Human Thymocyte Globulin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Melphalan chemotherapy",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Allogeneic hematopoietic stem cell transplantation (HSCT)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "High-risk pediatric and adolescent solid tumors",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 4,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neuroblastoma",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Refractory and recurrent solid tumors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Conditioning chemotherapy regimens (Thiotepa, Etoposide, Melphalan, Fludarabine)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Supportive immunosuppressive therapies (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Lapine T-Lymphocyte Immune Globulin)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial NCT04530487",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Transplant-related mortality and organ toxicity outcomes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Time to platelet and neutrophil engraftment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Graft-versus-host disease (GVHD) incidence and survival rates",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric and adolescent oncology clinical research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Delcath Systems, Inc. and HEPZATO KIT for liver cancer",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Targeted hepatic delivery of melphalan chemotherapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oncology drugs administration routes (IV and oral)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Soft tissue sarcomas and neuroectodermal tumors molecular genetics (EWSR1 translocation, MYCN amplification)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Reduced-intensity conditioning regimens in pediatric HSCT",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Melphalan",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Mycophenolate Mofetil",
                "count": 5,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Allogeneic Hematopoietic Stem Cell Transplantation",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor (DSRCT)",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor (MPNST)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Neuroblastoma",
                "count": 6,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Rhabdomyosarcoma",
                "count": 5,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Cyclosporine",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Etoposide",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Fludarabine Phosphate",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Melphalan",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Tacrolimus",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Thiotepa",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Immunosuppressive conditioning regimens",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial NCT04530487",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric and Adolescent High-Risk Solid Tumors",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Graft-versus-host disease (GVHD)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Transplant-related mortality (TRM)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chemotherapy in transplant conditioning",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Roche Pharmaceuticals",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Oncology therapeutics",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Roche anti-obesity drug development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Roche cell therapy acquisitions",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "EWS-WT1 fusion gene in DSRCT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "EWS-FLI1 fusion gene in Ewing Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "NF1 gene mutations in MPNST",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "MYCN amplification in Neuroblastoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "PAX3-FOXO1 fusion gene in Rhabdomyosarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Graft-versus-tumor effect",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Immunomodulatory agents in HSCT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial patient eligibility criteria for HSCT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Hematopoietic stem cell transplant donor suitability",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Mycophenolate Mofetil",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tacrolimus",
                "count": 6,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Cyclosporine",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Etoposide",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Fludarabine Phosphate",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Melphalan",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Mycophenolate Mofetil",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Thiotepa",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 7,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumor",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Neuroblastoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Rhabdomyosarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Allogeneic Hematopoietic Stem Cell Transplantation",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Graft-versus-Host Disease",
                "count": 3,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Transplant-related Mortality",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Organ Toxicity Grade III or Higher",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Platelet and Neutrophil Engraftment",
                "count": 1,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "High Risk Solid Tumors in Pediatric and Adolescent Patients",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "M.D. Anderson Cancer Center Clinical Trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Immunosuppressive Therapy in Transplantation",
                "count": 4,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Prograf (Tacrolimus)",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Advagraf (Extended-Release Tacrolimus)",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Envarsus XR (Extended-Release Tacrolimus)",
                "count": 2,
                "cluster": "Immunosuppressants and Conditioning Regimens in Hematopoietic Stem Cell Transplantation"
            },
            {
                "topic": "Astellas Pharma Inc.",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Veloxis Pharmaceuticals Inc.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "EWSR1-WT1 Fusion Gene in DSRCT",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Multimodal Treatment for DSRCT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Chromosomal Translocation t(11;22)(p13;q12)",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Immunosuppressant Drug Formulations (Oral, IV, Topical)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT04530487",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Rare Pediatric Soft Tissue Sarcomas",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            }
        ],
        "drug_generic_name": "Tacrolimus",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Thiotepa alkylating agent chemotherapy",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Hematopoietic stem cell transplantation conditioning regimen",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 6,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Ewing Sarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Refractory solid tumors pediatric and young adults",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT04530487 Phase II HSCT",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Cyclosporine immunosuppressive therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Etoposide chemotherapy drug intravenously",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fludarabine phosphate chemotherapy drug",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Lapine T-Lymphocyte Immune Globulin immunosuppression",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Melphalan chemotherapy drug",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mycophenolate mofetil immunosuppressant",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tacrolimus immunosuppressive drug",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Primary outcomes transplant-related mortality and toxicity",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Secondary outcomes graft-versus-host disease and engraftment",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric and adolescent young adult cancer patients",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "M.D. Anderson Cancer Center clinical research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Genetic EWSR1-WT1 fusion in DSRCT",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Aggressive soft tissue sarcoma treatment multimodal",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Amneal Pharmaceuticals oncology injectables and biosimilars",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Athenex Pharmaceutical Division oncology injectables",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Shorla Oncology pediatric oncology focus",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Thiotepa",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Botulinum toxin Type A",
                "count": 16,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "BOTOX\u00ae intramuscular injections",
                "count": 5,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Upper limb spasticity treatment",
                "count": 10,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Pediatric cerebral palsy spasticity",
                "count": 7,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Stroke-related muscle spasticity",
                "count": 5,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Phase 3 randomized clinical trial NCT01603602",
                "count": 6,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Modified Ashworth Scale-Bohannon (MAS-B) assessment",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Clinical Global Impression (CGI) outcome measure",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Goal Attainment Score (GAS) in spasticity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Modified Tardieu Scale (MTS) for spasticity severity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Botulinum toxin formulations and brand variants",
                "count": 5,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Neuromuscular blocking agents mechanism",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Botox FDA-approved indications for spasticity",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Occupational and physical therapy adjuncts",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Muscle relaxant oral medications (baclofen, tizanidine)",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Intrathecal baclofen therapy",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Orthotic devices for spasticity management",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Pediatric population ages 2 to 16 years in spasticity trials",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Muscle stiffness and hypertonia pathophysiology",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Major risk factors for upper limb spasticity (prematurity, brain injury, stroke)",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Botulinum toxin manufacturer companies",
                "count": 7,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "AbbVie commercial and R&D strategy for Botox",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Ipsen neurology and Botox licensing",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Merz Pharmaceuticals aesthetics and Botox marketing",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Revance Therapeutics DaxibotulinumtoxinA competitor",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Hugel Inc. Botulax botulinum toxin product",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Lanzhou Institute botulinum toxin manufacturing in China",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Neurological disorders causing spasticity",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Experimental therapies and gene therapy in spasticity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Global clinical trial sites for Botox in spasticity",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            }
        ],
        "drug_generic_name": "Botulinum toxin Type A",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Botulinum toxin Type A (BOTOX\u00ae) intramuscular injections",
                "count": 6,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Normal saline placebo injections",
                "count": 5,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Pediatric upper limb spasticity treatment",
                "count": 8,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Cerebral palsy-related muscle spasticity",
                "count": 6,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Stroke-induced upper limb spasticity",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Modified Ashworth Scale-Bohannon (MAS-B) assessment",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Clinical Global Impression (CGI) scale",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Goal Attainment Score (GAS) evaluation",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Modified Tardieu Scale (MTS) for spasticity severity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Phase 3 randomized double-blind clinical trial NCT01603602",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Botulinum toxin dosing (3 U/kg and 6 U/kg) in clinical study",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Physical and occupational therapy adjunct to injections",
                "count": 4,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Upper limb hypertonia in children",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Neurological pathophysiology of spasticity",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Botulinum toxin FDA approval for pediatric spasticity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Oral muscle relaxants (baclofen, tizanidine) for spasticity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Intrathecal baclofen therapy",
                "count": 1,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Orthotic devices for spasticity management",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Surgical interventions for severe spasticity (dorsal rhizotomy, tendon release)",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Gene therapy research for spasticity",
                "count": 1,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Neuroprosthetics and brain-computer interfaces for motor function restoration",
                "count": 1,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Placebo analgesic effects of normal saline injections",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Clinical trial masking methods (quadruple masking)",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Allergan pharmaceutical company operations and manufacturing",
                "count": 3,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Global distribution of clinical trial sites for pediatric spasticity",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            },
            {
                "topic": "Eligibility criteria for pediatric spasticity clinical trial",
                "count": 2,
                "cluster": "Botulinum Toxin and Spasticity Management"
            }
        ],
        "drug_generic_name": "Normal Saline",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Bicifadine SR 800 mg/day dosage",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Bicifadine SR 1200 mg/day dosage",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Chronic diabetic peripheral neuropathy pain",
                "count": 5,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Peripheral nervous system diseases",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Neuralgia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "XTL Biopharmaceuticals clinical trial sponsorship",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Mark Roffman principal investigator",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Phase 2 open-label safety study of Bicifadine",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Randomized parallel intervention model",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Pain and safety assessment over one year",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Clinical Global Impression of Improvement outcome",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "McGill Pain Questionnaire outcome",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Amount of rescue medication used for pain",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Quality of Life Survey (SF-36) outcome",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Patient Global Impression of Change outcome",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Adults with type 1 or type 2 diabetes inclusion criteria",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Exclusion criteria: psychiatric disorders and amputation",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Four Rivers Clinical Research site",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Bicifadine as serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Bicifadine non-opioid analgesic mechanism",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Bicifadine immediate-release and sustained-release formulations",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Bicifadine unapproved regulatory status in US and Europe",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Phase IIb trial termination due to lack of efficacy",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Phase III bicifadine trial showing pain relief comparable to codeine",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Wyeth Pharmaceuticals development and licensing history of Bicifadine",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "DOV Pharmaceutical licensing and rights transfers",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Chronic diabetic peripheral neuropathy disease characteristics",
                "count": 4,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "DPN epidemiology: prevalence and risk factors",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "DPN pathophysiology: hyperglycemia-induced nerve damage",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "DPN pharmacological treatments: anticonvulsants, antidepressants, topical agents",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Non-pharmacological management of DPN: glycemic control, foot care, physical therapy",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Alternative therapies for DPN: TENS, acupuncture, biofeedback",
                "count": 1,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Lifestyle modifications for DPN: smoking cessation, weight management",
                "count": 1,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Research in DPN: inflammation, gut microbiome, gene therapy, nanomedicine",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Corporate acquisitions: DOV Pharmaceutical acquisition by Euthymics Bioscience",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Euthymics Bioscience R&D pipeline including amitifadine for depression",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "XTL Biopharmaceuticals and DOV Pharmaceutical licensing agreement financial details",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Triple reuptake inhibitors for central nervous system disorders",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            }
        ],
        "drug_generic_name": "Bicifadine",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Subcutaneous Immunoglobulin Therapy for Myasthenia Gravis",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Myasthenia Gravis",
                "count": 6,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Hizentra (Immune Globulin Subcutaneous)",
                "count": 6,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Primary Immunodeficiency Treatment with Hizentra",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Chronic Inflammatory Demyelinating Polyneuropathy Treatment",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring pharmaceutical company",
                "count": 6,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Clinical Trial NCT01828294 for MG",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Steroid-Sparing Effect of Subcutaneous Immunoglobulin",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "FDA Approval of Hizentra 50mL Prefilled Syringe",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Phase I Clinical Trial of IGSC in Myasthenia Gravis",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Immunoglobulin Replacement Therapy",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Mechanism of Action of Hizentra",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Myasthenia Gravis Pathophysiology (AChR antibodies)",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "MG Treatments: Acetylcholinesterase Inhibitors",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "MG Treatments: Immunosuppressants",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "MG Treatments: Thymectomy",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "MG Treatments: Plasmapheresis and IVIg",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Complement Inhibitors in MG Research",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Gene Therapy for Myasthenia Gravis",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring R&D Pipeline (HEMGENIX, KOSTAIVE, Garadacimab)",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring Plasma Collection Network",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring Acquisitions (Vifor Pharma, Calimmune)",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "MG Epidemiology and Risk Factors",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            }
        ],
        "drug_generic_name": "Immune Globulin Subcutaneous (Human)",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Subcutaneous immunoglobulin therapy for Myasthenia Gravis",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Myasthenia Gravis clinical trial NCT01828294",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Hizentra (Immune Globulin Subcutaneous) drug",
                "count": 4,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Primary Immunodeficiency treatment with Hizentra",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) maintenance therapy",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Myasthenia Gravis disease characteristics and treatment",
                "count": 4,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Complement inhibitors efgartigimod alfa and zilucoplan for MG",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring company overview and biopharmaceutical portfolio",
                "count": 4,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring pipeline drugs: HEMGENIX, KOSTAIVE, Garadacimab",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring manufacturing and global plasma collection network",
                "count": 3,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "CSL Behring recent acquisitions: Vifor Pharma and Calimmune",
                "count": 2,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            }
        ],
        "drug_generic_name": "Immune Globulin Subcutaneous (Human), 20% Liquid",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "MC-5A Calmare device",
                "count": 7,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Chemotherapy-induced peripheral neuropathy (CIPN)",
                "count": 5,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Scrambler Therapy",
                "count": 3,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Paraneoplastic neuropathy",
                "count": 5,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Peripheral Nervous System Diseases",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Randomized, double-blind sham-controlled clinical trial",
                "count": 3,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Transcutaneous electrical nerve stimulation (TENS)",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "University of Wisconsin Madison clinical study",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Calmare Therapeutics Incorporated",
                "count": 4,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Non-invasive pain management devices",
                "count": 3,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Pain measurement via Mechanical Visual Analog Scale (mVAS) and Quantitative Sensory Pain Testing (QSPT)",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Immunotherapy for paraneoplastic neuropathy",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Plasma exchange and intravenous immunoglobulin therapy",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Physical therapy for neuropathy symptoms",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "FDA and CE clearance/status of Calmare device",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Clinical trial identifier NCT01261780",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "CTCAE adverse event tracking",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Calmare Therapeutics military GSA contract",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Clinical trial phases (Phase 2)",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Electrostimulation pain modulation techniques",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            }
        ],
        "drug_generic_name": "MC-5A",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "MC-5A medical device for chemotherapy-induced peripheral neuropathy",
                "count": 4,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Sham device placebo control in clinical trials",
                "count": 4,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Chemotherapy-induced peripheral neuropathy (CIPN)",
                "count": 3,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Paraneoplastic neuropathy (Paraneoplastic peripheral neuropathy)",
                "count": 4,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Peripheral nervous system diseases",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Clinical trial NCT01261780 phase 2",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "University of Wisconsin\u2013Madison clinical research",
                "count": 3,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Quantitative Sensory Pain Testing (QSPT)",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Mechanical Visual Analog Scale (mVAS) pain measurement",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Immune-mediated nerve damage in paraneoplastic neuropathy",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Autoantibodies anti-Hu and anti-CV2/CRMP-5 in paraneoplastic neuropathy",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Pain management in chemotherapy-induced neuropathy",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Triple masking in clinical trial design",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Randomized double-blind sham-controlled clinical trial",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Waisman Biomanufacturing cGMP manufacturing support",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Wisconsin Alumni Research Foundation (WARF) technology transfer",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Radiopharmaceutical Production Facility at UW-Madison",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Regenerative medicine research at UW-Madison",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Clinical Trials Institute at UW-Madison",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            }
        ],
        "drug_generic_name": "Sham Device",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Nipocalimab intravenous infusion",
                "count": 4,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Nipocalimab FcRn inhibition mechanism",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Generalized Myasthenia Gravis treatment",
                "count": 5,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Nipocalimab Phase 3 clinical trial Vivacity-MG3",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Monoclonal antibody therapies for autoimmune diseases",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Myasthenia Gravis - Activities of Daily Living (MG-ADL) score",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Quantitative Myasthenia Gravis (QMG) score",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled clinical trials",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Autoimmune diseases targeted by Nipocalimab",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Janssen Research & Development, LLC",
                "count": 4,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Nipocalimab investigational drug status and regulatory review",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Myasthenia Gravis pathophysiology - autoantibodies AChR, MuSK, LRP4",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Immunosuppressive and plasma exchange therapies for MG",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Complement inhibition therapies under investigation for MG",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Neuromuscular Research Center clinical trial site",
                "count": 1,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Clinical trial inclusion and exclusion criteria for generalized MG",
                "count": 1,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Adverse events and safety profile in nipocalimab trials",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Warm Autoimmune Hemolytic Anemia treated by Nipocalimab",
                "count": 1,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
                "count": 1,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Idiopathic Inflammatory Myopathies",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Sj\u00f6gren\u2019s Disease",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Systemic Lupus Erythematosus (SLE)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Rheumatoid Arthritis",
                "count": 1,
                "cluster": "Autoimmune Muscle and Skin Inflammation: Abatacept and Dermatomyositis"
            },
            {
                "topic": "Johnson & Johnson pharmaceutical R&D and commercial strategy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Janssen manufacturing facilities for biologics",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Global distribution and supply chain of Johnson & Johnson",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Nipocalimab dose-ranging Phase 2 VIVACITY-MG study",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Nipocalimab patent and exclusivity status",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Demographics and epidemiology of generalized Myasthenia Gravis",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Nipocalimab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Nipocalimab intravenous infusion",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Myasthenia Gravis treatment",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Generalized Myasthenia Gravis",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 clinical trial NCT04951622",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "JNJ-80202135 (Nipocalimab)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Placebo as comparator in clinical trials",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Triple masking in randomized trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Myasthenia Gravis - Activities of Daily Living (MG-ADL) score",
                "count": 3,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Immunosuppressive therapies for Myasthenia Gravis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Acetylcholinesterase inhibitors",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Thymectomy surgical treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Complement inhibitors in Myasthenia Gravis",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical therapy for muscle weakness",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Autoimmune neuromuscular disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anti-FcRn monoclonal antibody therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular junction antibody pathophysiology",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "International multicenter trial sites",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Janssen Research & Development sponsorship",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sun Pharmaceutical therapeutic areas and manufacturing",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Placebo",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Sodium Oxybate (Xyrem) dosing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia clinical trial NCT00423605",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia symptoms and management",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Myofascial Pain Syndromes relevance",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Jazz Pharmaceuticals drug development",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Central Nervous System depressants",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia genetics and risk factors",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia epidemiology and demographics",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Sodium Oxybate mechanism of action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sodium Oxybate regulatory approval status",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia treatments: antidepressants and anticonvulsants",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia alternative therapies (acupuncture, massage)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia research on gut microbiome and neuromodulation",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Jazz Pharmaceuticals R&D pipeline for neuroscience",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Jazz Pharmaceuticals mergers and acquisitions",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Restricted distribution programs for controlled substances",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Sodium Oxybate patent protection and exclusivity",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Clinical trial safety and adverse events monitoring",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia risk factors: genetic, lifestyle, environmental",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            }
        ],
        "drug_generic_name": "Sodium Oxybate",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Dimiracetam",
                "count": 12,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Treatment-Induced Painful Neuropathy in HIV-Infected Patients",
                "count": 7,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "HIV-associated neuropathic pain",
                "count": 5,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Antiretroviral therapy (ART)-induced neuropathy",
                "count": 5,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "N-methyl-D-aspartate (NMDA) receptor antagonist",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial of Dimiracetam (NCT01135251)",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Neurotune AG",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain management in HIV",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral Nervous System Diseases",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Clinical trial methodology: randomized, double-blind, placebo-controlled",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular diseases drug development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Escalating oral dosing regimen",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Safety and tolerability of Dimiracetam",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Visual Analog Scale (VAS) for pain assessment",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Antiretroviral therapy adverse effects",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain symptomatic treatments (gabapentin, pregabalin, amitriptyline)",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Coenzyme Q10 neuroprotective effects in neuropathy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Dideoxynucleosides (d-drugs) mitochondrial toxicity",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial sites: Port Elizabeth, South Africa",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Placebo comparator in neuropathic pain trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Nootropic drugs for neurological disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Dosage escalation based on tolerability",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "HIV viral load and CD4+ T cell count monitoring in trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurological symptom progression patterns (stocking and glove distribution)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Lifestyle modifications for neuropathic pain relief",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Nutrient therapies for neuropathy (B vitamins)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Topical treatments for neuropathic pain (capsaicin, lidocaine)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Phase IIa trial positive results for Dimiracetam",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Clinical trial exclusions: pregnancy, psychiatric history, other neuropathies",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Drug development pipeline of Neurotune AG",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Dimiracetam",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Vigabatrin",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Infantile Spasms",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "West Syndrome",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics of Vigabatrin in infants",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT01413711",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Treatment of refractory complex partial seizures",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Treatment of infantile spasms with Vigabatrin",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Vigafyde oral solution formulation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of action: GABA-AT inhibition",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Infant epilepsy treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "ILAE diagnostic criteria for infantile spasms",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Safety assessment of Vigabatrin in infants",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "H. Lundbeck A/S pharmaceutical company",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Lundbeck acquisition of Longboard Pharmaceuticals",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pyros Pharmaceuticals licensing and marketing of Lundbeck products",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroids in infantile spasms treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adrenocorticotropic hormone (ACTH) therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketogenic diet for treatment-resistant infantile spasms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical intervention for brain lesions causing spasms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic and metabolic research on infantile spasms",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Hypsarrhythmia EEG pattern in infantile spasms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label uses of Vigabatrin (e.g. SSADHD, panic disorder)",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Vigabatrin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "CEP-37247 (Placulumab)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Transforaminal epidural administration",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sciatica (lumbosacral radicular pain)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Intervertebral Disc Displacement (Disc Herniation)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1/Phase 2 clinical trial NCT01240876",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Randomized double-blind placebo-controlled trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody targeting TNF-alpha",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "TNF-alpha inhibition for inflammatory pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rheumatoid arthritis preclinical efficacy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cephalon as study sponsor and developer",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Teva Pharmaceutical Industries acquisition of Cephalon",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pain intensity measurement (Average Pain Intensity, API)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria: MRI-confirmed lumbosacral radicular pain and NRS-11 pain score \u22655",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial sites in United States and Australia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse event monitoring in clinical trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-approval and discontinued development of Placulumab",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sciatica epidemiology and risk factors",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Spinal stenosis, piriformis syndrome, deep gluteal syndrome as sciatica causes",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "First-line treatment: NSAIDs, muscle relaxants, physical therapy, epidural steroid injections",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Alternative sciatica therapies: acupuncture, chiropractic care",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Surgical treatment for severe sciatica (discectomy, laminectomy)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Research on biologics, gene therapy, neurostimulation for sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Teva's therapeutic focus on CNS disorders, respiratory diseases, oncology",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial design elements: triple masking, parallel intervention model, randomization",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Placulumab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "SAR443820 drug",
                "count": 10,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "RIPK1 inhibitor",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 15,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Motor Neuron Disease",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical trial NCT05797701",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase 1 clinical trial",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase 2 clinical trials in ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase 2 clinical trials in Multiple Sclerosis",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neurological disorders therapeutic development",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Sanofi pharmaceutical company",
                "count": 7,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Denali Therapeutics biotechnology company",
                "count": 6,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neurodegenerative diseases treatment research",
                "count": 5,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Oral tablet and capsule formulations",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Bioavailability and food-effect study",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuroinflammation modulation",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS epidemiology and risk factors",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS gene mutations (SOD1, C9orf72, TARDBP, FUS)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS treatment and management strategies",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Riluzole and Edaravone use in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS clinical trial discontinuations",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neurodegeneration mechanisms (necroptosis, inflammation)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Sanofi-Denali strategic partnership on RIPK1",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Multiple sclerosis (MS) clinical research",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Alzheimer's disease research",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical pharmacokinetics endpoints (Cmax, AUC)",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Pharmacokinetic crossover study design",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            }
        ],
        "drug_generic_name": "SAR443820",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Iodinated Activated Charcoal (IodoCarb\u00ae)",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Fatigue Syndrome (CFS)",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Myalgic Encephalomyelitis (ME)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1 and 2a Clinical Trial NCT01793415",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Mercury Toxicity Mitigation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "PharmaLundensis AB",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Quality of Life Measurement in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Psychotropic Drug Use in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Physical Activity Monitoring with Pedometer in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Iodine Allergy and Thyroid Function Exclusion Criteria",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Immune System Alterations in CFS",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Energy Metabolism Disruption in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuroendocrine Dysregulation in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Autonomic Nervous System Dysfunction in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gastrointestinal Involvement in CFS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Graded Exercise Therapy (GET) for CFS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cognitive Behavioral Therapy (CBT) for CFS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological Symptom Management in CFS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Design: Randomized Double-Masked Parallel Intervention",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Patient Eligibility Criteria (Age 35-60) for CFS Trial",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Iodinated Activated Charcoal",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Pyridostigmine (Mestinon)",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Exercise intervention in fibromyalgia",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Attention control intervention",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled trial",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Cholinesterase inhibitor mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial NCT00535587",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Growth hormone measurement post-exercise",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Improvement of fibromyalgia symptoms",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Myofascial pain syndromes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label pyridostigmine uses",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Musculoskeletal and neurological disorder",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Central sensitization theory of fibromyalgia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cytokine inflammation theory",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Small fiber neuropathy in fibromyalgia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Muscle hypoxia theory",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Muscle tender point theory",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Antidepressants for fibromyalgia management",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsants for fibromyalgia management",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cognitive behavioral therapy in fibromyalgia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical therapy and exercise for fibromyalgia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromodulation techniques (TMS)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gut microbiome research in fibromyalgia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "National Institute of Nursing Research (NINR)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oregon Health and Science University clinical research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Bausch Health Companies pharmaceutical manufacturing",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Sun Pharmaceutical Industries global operations",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Mylan Pharmaceuticals and Viatris merger",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Teva Pharmaceutical Industries specialty generics",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            }
        ],
        "drug_generic_name": "Pyridostigmine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "sNN0029 Intracerebroventricular Infusion",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS) Treatment",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "VEGF165 Growth Factor Therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "ICV Drug Delivery System",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1/Phase 2 Clinical Trials of sNN0029",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neurological Motor Neuron Disease",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "ALS Functional Rating Scale (FRS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Safety and Tolerability in ALS Trials",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "SOD1 and C9orf72 Genetic Mutations in ALS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Newron Pharmaceuticals R&D Pipeline",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Implanted Catheter and SynchroMed\u00ae II Pump System",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS Disease Epidemiology and Risk Factors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Supportive and Adjunct Therapies for ALS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuroprotection via Angiogenesis in ALS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Termination Due to Infusion System Issues",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS Pathophysiology and Protein Aggregates",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Newron Pharmaceuticals Strategic Partnerships and Licensing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Recombinant Human Vascular Endothelial Growth Factor 165 (rhVEGF-165)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS Investigational Drug Development",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Newron Pharmaceuticals Manufacturing and Global Presence",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Recombinant Human Vascular Endothelial Growth Factor 165 (rhVEGF-165)",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Calcitonin therapy for neuropathic pain after spinal cord injury",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain following spinal cord injury",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Calcitonin drug information and formulations",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Randomized clinical trial NCT05805683",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Spinal cord injury",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Calcitonin mechanism of action on bone resorption and analgesia",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological management of neuropathic pain (anticonvulsants, antidepressants, opioids)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Calcitonin use in osteoporosis and Paget's disease",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria and study design details for calcitonin trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tanta University clinical research on calcitonin",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Eli Lilly and Company as original developer of calcitonin",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Generic manufacturers of calcitonin including Amgen and Novartis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pathophysiology of neuropathic pain (dorsal horn hyperexcitability, sodium channel changes, CGRP sprouting)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmacological treatments for neuropathic pain (physical therapy, TENS, psychological support)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain intensity and chronic pain incidence as primary and secondary outcomes in calcitonin trial",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Calcitonin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tirasemtiv (CK-2017357) drug",
                "count": 9,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 13,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Riluzole (Rilutek) drug",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "BENEFIT-ALS Phase IIb clinical trial",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS Functional Rating Scale-Revised (ALSFRS-R)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Slow Vital Capacity (SVC) as outcome measure",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Muscle strength measurements in ALS studies",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Cytokinetics, Inc. as lead sponsor and developer",
                "count": 7,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase III VITALITY-ALS trial on tirasemtiv",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Peripheral Artery Disease (PAD) clinical trial of tirasemtiv",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Skeletal muscle troponin activators",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuromuscular disease therapeutics",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Motor neuron disease synonyms for ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Muscle activators as therapeutic strategy",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Gene mutations associated with ALS (C9orf72, SOD1, TARDBP, FUS)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Non-pharmaceutical ALS management (Physical, Occupational, Speech therapy)",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Respiratory support in ALS (non-invasive ventilation)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "R&D pipeline drugs by Cytokinetics (aficamten, omecamtiv mecarbil, reldesemtiv, CK-136)",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical trial design features: randomized, placebo-controlled, quadruple masking",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Drug dosing regimen: tirasemtiv 125 mg to 500 mg twice daily",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            }
        ],
        "drug_generic_name": "Tirasemtiv",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Incobotulinum Toxin A (Xeomin)",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Troublesome sialorrhea treatment",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Parkinson Disease",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 6,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Randomized double blind placebo controlled crossover study",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Botulinum toxin injections for sialorrhea",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Beth Israel Deaconess Medical Center",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Merz Pharmaceuticals",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Neurological movement disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT01565395",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Salivary volume measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Parkinsonism",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "UPDRS Part 2 sialorrhea grading scale",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Botulinum toxin type A purity and mechanism",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anticholinergic medications for sialorrhea",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Speech and swallowing therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical interventions for sialorrhea",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oral motor training and dietary modifications",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "SIAXI study",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Neurology-focused pharmaceutical manufacturing facilities",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Merz Pharmaceuticals strategic acquisitions",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inbrija and Ampyra (neurology drugs)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Xeomin FDA and EMA approval status",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial recruitment challenges",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Saline placebo injection",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Incobotulinum Toxin A",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Lamotrigine",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Myotonia Treatment Clinical Trial NCT01939561",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Non-Dystrophic Myotonias (NDMs)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Myotonia Behavior Scale (MBS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mexiletine treatment for myotonia",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sodium channel blockers for myotonia",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Dystrophia Myotonica Type 1",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Myotonia Congenita",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Paramyotonia Congenita",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Hyperkalemic Periodic Paralysis",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Potassium-Aggravated Myotonia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 randomized controlled trial design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Lamotrigine mechanism of action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label uses of Lamotrigine",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "SF-36 quality of life questionnaire",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Copenhagen Neuromuscular Center research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Channelopathy gene SCN4A mutations",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Alternative sodium channel blockers (lacosamide, rufinamide)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "GlaxoSmithKline Lamotrigine development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Bausch Health Companies Lamotrigine marketing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Generic manufacturers Teva and Mylan",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Lamotrigine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Methylprednisolone",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Muscle Weakness",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "CORTERAS Study",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 4 Clinical Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroid Use in Surgery",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Inflammatory Response",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Strength Assessment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Elderly Surgical Patients",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "NaCl 0.9% Placebo",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Parallel Intervention Model",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Musculoskeletal Disorders",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Fatigue",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Quality of Recovery Metrics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Steroid Mechanism of Action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Glucocorticoid Receptor Binding",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Manufacturers of Methylprednisolone",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Viatris Pharmaceutical Company",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Pharmaceutical Company",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Merck Pharmaceutical Company",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Generic Drug Producers",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Atrophy and Rehabilitation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Physical Rehabilitation for Post-Surgery Weakness",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Electrical Stimulation",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Anabolic Agents for Muscle Strength",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Nutritional Support in Postoperative Recovery",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exclusion Criteria in Clinical Trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Handgrip Strength Measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical Trauma Effects on Muscle",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Methylprednisolone",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "5% Lidocaine Medicated Plaster",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Localized Chronic Postoperative Neuropathic Pain",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain",
                "count": 5,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Chronic Pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 Clinical Trial NCT01752322",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal GmbH",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled Randomized Double-blind Study",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Topical Hydrogel Plaster Formulation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Neuropathic Pain Treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pain Intensity Outcome Measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse Skin Reactions to Lidocaine Patch",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic Neuralgia",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Local Anesthetic Mechanism of Action (Sodium Channel Blockade)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label Uses of Lidocaine Patch",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "FDA, EMA, MHRA Approval Status for Lidocaine Patch",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Antidepressants and Anticonvulsants as Adjunct Therapies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Alternative Pain Management Therapies (TENS, Physical Therapy, CBT)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromodulation and Nerve Blocks Research",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Global Multinational Clinical Trial Locations",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal R&D Pipeline: Resiniferatoxin (RTX)",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal R&D Pipeline: Qutenza\u2122 Topical Treatment",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal R&D Pipeline: NOP Receptor Agonist",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal R&D Pipeline: Glucocorticoid Receptor Modulator",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Strategic Partnerships and Licensing Deals",
                "count": 3,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Manufacturing Facilities in Europe and Latin America",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Gr\u00fcnenthal Acquisitions: Nebido\u2122, Thar Pharmaceuticals, Averitas Pharma",
                "count": 3,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            }
        ],
        "drug_generic_name": "Lidocaine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Lacosamide",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Painful Diabetic Neuropathy",
                "count": 6,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Diabetic Neuropathic Pain Management",
                "count": 4,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Clinical Trial NCT00220337",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsant Therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 Open-label Trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurological Disorders Treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sodium Channel Blockers",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Partial-Onset Seizures",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Neuropathy Epidemiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain Management Outcomes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin and Gabapentin",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Tricyclic Antidepressants for Neuropathy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Topical Analgesics for Neuropathy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Alternative Therapies for PDN",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "UCB S.A. Company Profile",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Manufacturing Facilities",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma Acquisitions (Celltech, Schwarz Pharma)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Lacosamide Mechanism of Action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Lacosamide Drug Formulations",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Lacosamide Patent Expiration",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Lacosamide",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Chenodeoxycholic acid therapy",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Cholic acid therapy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Ursodeoxycholic acid use",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Peroxisomal disorders treatment",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Infantile Refsum's disease",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Zellweger syndrome",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Bifunctional enzyme deficiency",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adrenoleukodystrophy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT00004442",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Leadiant Biosciences, Inc.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mirum Pharmaceuticals, Inc.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Bile acid synthesis disorders",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Cerebrotendinous xanthomatosis treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cholesterol gallstone dissolution with CDCA",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Peroxisome biogenesis disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene therapy for peroxisomal disorders",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Farnesoid X receptor (FXR) activation by CDCA",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric peroxisomal disorder patients",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Children's Hospital Medical Center, Cincinnati",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Chenodeoxycholic acid",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Dexamethasone Submucosal Injection After Third Molar Surgery",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Edema Following Mandibular Third Molar Extraction",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Trismus Following Mandibular Third Molar Extraction",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Controlled Trial of Dexamethasone for Postoperative Complications",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroid Use in Oral and Maxillofacial Surgery",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT06953440",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Dexamethasone Sodium Phosphate Injection",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 4 Interventional Study on Postoperative Complications",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Swelling Reduction After Wisdom Tooth Extraction",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Trismus Reduction After Wisdom Tooth Extraction",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "King Abdulaziz University Dental Research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Manufacturers of Dexamethasone Sodium Phosphate Injection",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Companies Pfizer, Teva, and Viatris",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Anti-inflammatory Effects of Dexamethasone",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Outcomes Assessment Post-Dexamethasone Injection",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Submucosal Corticosteroid Administration Techniques",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Dexamethasone Sodium Phosphate",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Amiloride neuroprotection in optic neuritis",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Optic Neuritis clinical trial ACTION NCT01802489",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Optic Neuritis pathophysiology and treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Amiloride potassium-sparing diuretic use in hypertension and heart failure",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "University of Oxford neuroprotection research in optic neuritis",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Multiple Sclerosis association with optic neuritis",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Amiloride acid-sensing ion channel blockade",
                "count": 2,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Optic Neuritis epidemiology and risk factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Amiloride dosage and formulation (10 mg capsule)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Merck & Co. manufacturing and commercialization of Midamor (amiloride)",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Amiloride",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "NXN-462 selective nNOS inhibitor",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Post-Herpetic Neuralgia (PHN) treatment",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain management",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 randomized placebo-controlled clinical trial",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Oral twice-daily dosing regimen",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial outcome measures for PHN",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "nNOS enzyme inhibition mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "NeurAxon Inc. pharmaceutical research",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pain score reduction endpoints",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Chronic neuropathic pain conditions",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "PHN epidemiology and risk factors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "PHN pathophysiology related to varicella zoster virus",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "PHN standard of care treatments (anticonvulsants, antidepressants, topical agents)",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Interventional therapies for neuropathic pain (nerve blocks, spinal cord stimulation)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Alternative therapies for PHN (opioids, TENS, acupuncture)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "NeurAxon acquisition by Knight Therapeutics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "NXN-188 and NXN-677 preclinical pipeline drugs",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Selective targeting of neuronal NOS isoform to reduce side effects",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Study inclusion and exclusion criteria for PHN trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Geographically diverse U.S. and Canadian clinical trial sites",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "NXN-462",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Simvastatin usage in clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Statin-Induced Myopathy (SIM)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Muscle-related adverse effects of statins",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial changes in skeletal muscle during statin therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Statins as HMG-CoA reductase inhibitors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Simvastatin pharmacology and mechanism of action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Statin-associated muscle symptoms epidemiology and genetics",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT04507373",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "University of Texas Southwestern Medical Center as clinical trial sponsor",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Merck & Co. company profile and strategic initiatives",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Simvastatin indications including familial hypercholesterolemia and cardiovascular risk reduction",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Alternative lipid-lowering therapies and statin intolerance management",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic variants affecting statin myopathy risk (SLCO1B1)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial design features: phase 4, randomized, triple masking, single-group intervention",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Simvastatin formulations and dosages",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Statin adverse reaction monitoring and management strategies",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Simvastatin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "E-CEL UVEC cell therapy",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Rotator cuff tear treatment",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Supraspinatus tendon repair",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Adjunct cell therapy for rotator cuff repair",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Anal fistula cell therapy trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Chronic anal fissure cell therapy trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1 clinical trials for E-CEL UVEC",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Hospital for Special Surgery clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Angiocrine Bioscience cell therapy development",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Engineered human umbilical vein endothelial cells",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Muscle atrophy related to tendon injury",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Rotator cuff injury epidemiology and risk factors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Arthroscopic rotator cuff repair surgery",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Safety assessment of cell therapy post-surgery",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "MRI evaluation of rotator cuff repair outcomes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Re-tear rates monitoring after tendon repair",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Regenerative medicine for musculoskeletal injuries",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Cell therapy manufacturing using Quantum Cell Expansion System",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical-stage biotechnology companies in cell therapies",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "E-CEL UVEC",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Daratumumab",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "POEMS Syndrome",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "CD38 molecule targeting",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody therapy",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Lenalidomide combination therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Multiple myeloma treatment",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT04396496",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "University of Arkansas for Medical Sciences",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Janssen Biotech Johnson & Johnson",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of action by ADCC, CDC, ADCP",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "VEGF role in POEMS syndrome",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Radiation therapy for POEMS syndrome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Chemotherapy regimens for POEMS syndrome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Autologous hematopoietic cell transplantation",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Immunomodulatory drugs (thalidomide, lenalidomide) in POEMS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Subcutaneous daratumumab formulation",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody induced NK cell depletion",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical outcomes: ECOG and ONLS scores",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mayo Clinic POEMS syndrome daratumumab research",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Johnson & Johnson pharmaceutical manufacturing capacity",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Johnson & Johnson oncology and immunology therapeutic focus",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Johnson & Johnson recent acquisitions (Abiomed, Ambrx, Shockwave Medical, Proteologix)",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            }
        ],
        "drug_generic_name": "Daratumumab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Ketamine for refractory chronic cancer pain",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine administration protocols",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Refractory cancer pain",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain in cancer patients",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Opioid use and reduction in chronic pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial KETACANCER (NCT04459234)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Esketamine (Spravato) for treatment-resistant depression",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "NMDA receptor antagonists mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine formulations and delivery routes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Quality of life outcomes in cancer pain treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine analgesic efficacy and tolerance profile",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Prospective multicenter observational study design",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cancer types: solid tumors and hematological malignancies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exclusion criteria for Ketamine cancer pain studies",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "French cancer centers clinical trials network",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "FDA, EMA, MHRA approvals for Ketamine and Esketamine",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine's use in veterinary and human anesthesia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Alternate therapies for refractory cancer pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse effects of Ketamine (hallucinations, dissociation)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Psychological support and cognitive behavioral therapy for pain",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Johnson & Johnson pharmaceutical company profile",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Esketamine commercialization and patent exclusivity",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chronic graft versus host disease as related condition",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine in depression and psychiatric disorders research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine clinical trials results in chronic pain and depression",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Research on NMDA receptor antagonism for pain sensitization",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cancer pain epidemiology and risk factors",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Palliative interventions (nerve blocks, radiation) for pain",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Multidisciplinary approaches to refractory cancer pain management",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Ketamine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Topical Capsaicin 0.025% Gel for Diabetic Polyneuropathy",
                "count": 3,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Painful Diabetic Neuropathy Clinical Trial NCT00993070",
                "count": 3,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Capsaicin Mechanism of Action via TRPV1 and Substance P Depletion",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Capsaicin Brand Names Including Qutenza, Zostrix, Capzasin, Salonpas",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Capsaicin Formulations: Creams, Gels, and High-Concentration Patches",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Diabetic Polyneuropathy Epidemiology and Risk Factors",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Neuropathic Pain Management with Topical Analgesics",
                "count": 3,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Diabetic Polyneuropathy Treatment: Glycemic Control, Antidepressants, Anticonvulsants, Capsaicin",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Astellas Pharma Inc. and Qutenza 8% Capsaicin Patch",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Capsaicin Off-Label Use for Diabetic Neuropathy and Pruritus",
                "count": 2,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Clinical Outcomes Measured by Visual Analog Scale and Clinician Global Impression",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inclusion and Exclusion Criteria for Capsaicin Neuropathy Clinical Trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Manufacturer Companies of Capsaicin Products (Chattem, Hisamitsu Pharmaceutical)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Neuropathy Symptoms and Complications Including Foot Ulcers",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Research and Innovations in Diabetic Polyneuropathy Including \u03b1-Lipoic Acid and Gene Therapy",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Capsaicin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Ribociclib",
                "count": 11,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Doxorubicin Hydrochloride",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Advanced Soft Tissue Sarcoma",
                "count": 14,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Locally Advanced Angiosarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Locally Advanced Leiomyosarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Locally Advanced Liposarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Locally Advanced Malignant Peripheral Nerve Sheath Tumor",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Locally Advanced Myxofibrosarcoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Locally Advanced Undifferentiated Pleomorphic Sarcoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Angiosarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Metastatic Epithelioid Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Fibrosarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Liposarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Malignant Peripheral Nerve Sheath Tumor",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Myxofibrosarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Soft Tissue Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Synovial Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Metastatic Undifferentiated Pleomorphic Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Myxofibrosarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Pleomorphic Rhabdomyosarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Stage III Soft Tissue Sarcoma AJCC v7",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Stage IV Soft Tissue Sarcoma AJCC v7",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Undifferentiated (Embryonal) Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Unresectable Leiomyosarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Unresectable Liposarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Unresectable Malignant Peripheral Nerve Sheath Tumor",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Unresectable Soft Tissue Sarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Unresectable Synovial Sarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Unresectable Undifferentiated Pleomorphic Sarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Cyclin-dependent kinase (CDK) 4/6 inhibitor",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Phase 1B Clinical Trial NCT03009201",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Dose-limiting toxicities (DLTs)",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Progression-free survival (PFS)",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Objective response rate (ORR)",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Adverse events and serious adverse events (SAEs)",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Chemotherapy in Soft Tissue Sarcoma",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Immunotherapy in Soft Tissue Sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Targeted Therapy in Soft Tissue Sarcoma",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "OHSU Knight Cancer Institute",
                "count": 4,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Novartis Pharmaceuticals",
                "count": 4,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Astex Pharmaceuticals",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "CDK4/6 inhibitors in cancer therapy",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Cell cycle arrest by Ribociclib",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Oncogenic mechanisms in Soft Tissue Sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Advanced Soft Tissue Sarcoma epidemiology",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Genetic risk factors for Soft Tissue Sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Li-Fraumeni syndrome",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Neurofibromatosis type 1",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Immunotherapy and checkpoint inhibitors",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Clinical trial drug dosing schedules",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Pharmaceutical manufacturing and global supply chains",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Novartis Strategic Partnerships and Acquisitions",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Global distribution of oncology drugs",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            }
        ],
        "drug_generic_name": "Ribociclib",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Paclitaxel chemotherapy regimen",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Elasto-Gel\u2122 cryotherapy mitts and slippers",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Breast cancer treatment",
                "count": 4,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Paclitaxel-induced peripheral neuropathy (CIPN)",
                "count": 6,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Regional cryotherapy for neuropathy prevention",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Phase II interventional clinical trial NCT03429972",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Patient Neurotoxicity Questionnaire (PNQ) outcome measure",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Dose-dependent neurotoxicity risk factors",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "National Cancer Centre Singapore clinical research",
                "count": 4,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Gabapentin and duloxetine symptomatic management for CIPN",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Cryotherapy as non-pharmaceutical management of CIPN",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Neuroinflammatory pathways in CIPN pathophysiology",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Bristol-Myers Squibb oncology portfolio including Abraxane",
                "count": 3,
                "cluster": "Bristol-Myers Squibb Oncology and Neuroscience Acquisitions"
            },
            {
                "topic": "Albumin-bound paclitaxel (Abraxane) formulation and patent",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Chemotherapy-induced peripheral neuropathy epidemiology and risk factors",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Paclitaxel",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Pregabalin",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin safety in fibromyalgia clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Inc.",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Partial-onset seizures treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia treatment with pregabalin",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia symptoms and epidemiology",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin formulation and dosage forms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin mechanism of action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin adverse effects and safety considerations",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia non-pharmacologic treatments",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia pharmacologic treatments",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin FDA and international approvals",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin patent and generic availability",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin off-label uses",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia research and novel therapies",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer manufacturing and commercial strategy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer oncology acquisition of Seagen",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Pregabalin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Trazodone use in Fibromyalgia treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin use in Fibromyalgia treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia clinical trial NCT00791739",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia Impact Questionnaire",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia disease characteristics and epidemiology",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia management with antidepressants and anticonvulsants",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia secondary symptoms assessment (sleep quality, pain, depression, anxiety)",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Trazodone pharmacology and formulations",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer pharmaceutical company profile",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Angelini Pharma pharmaceutical company profile",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology involving central sensitization and neurotransmitters",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia non-pharmaceutical treatments (CBT, physical therapy, acupuncture, mindfulness)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia novel research areas (gut microbiome, neuromodulation, biological agents)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia risk factors (genetic, lifestyle, environmental)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial design and outcome measures in fibromyalgia drug studies",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Trazodone",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Oxycodone",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Famciclovir",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic Neuralgia",
                "count": 6,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Pain management in Herpes Zoster",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT03120962",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Visual analogue scale pain measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antiviral therapy for Herpes Zoster",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Opioid analgesics",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pain intensity assessment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic neuralgia prevention",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster vaccination (Shingrix)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsants for PHN (gabapentin, pregabalin)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tricyclic antidepressants for PHN",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Topical agents for PHN (lidocaine patches, capsaicin)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Second Affiliated Hospital, Zhejiang University",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Purdue Pharma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Teva Pharmaceutical Industries Ltd.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mylan N.V. / Viatris Inc.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Opioid receptor mechanism of oxycodone",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster epidemiology and risk factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster pathophysiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antiviral drugs acyclovir and valacyclovir",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for herpes zoster clinical trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Opioid addiction and misuse risks",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical company opioid litigation",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Oxycodone",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Drisapersen",
                "count": 19,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 20,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Antisense oligonucleotide therapy",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon 51 skipping",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Subcutaneous injection formulation",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Phase 3 clinical trial (NCT01890798)",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Drisapersen clinical trial withdrawal",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Adverse events in drisapersen trials",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Efficacy failure of drisapersen",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "BioMarin Pharmaceutical",
                "count": 12,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Prosensa acquisition by BioMarin",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Neuromuscular disorders treatment development",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "DMD pathophysiology (dystrophin deficiency)",
                "count": 7,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "DMD epidemiology and patient demographics",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "DMD standard of care treatments (corticosteroids, physical therapy)",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Gene therapy for DMD (e.g., Elevidys)",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon skipping drugs for DMD (eteplirsen, golodirsen)",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "CRISPR-Cas9 gene editing research in DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Utrophin upregulation research",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Parent Project Muscular Dystrophy research funding",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "BioMarin manufacturing sites (Novato and Shanbally)",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "BioMarin R&D pipeline drugs (BMN 351, BMN 333, BMN 349)",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "BioMarin market and financial data",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "BioMarin global distribution and licensing strategy",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            }
        ],
        "drug_generic_name": "Drisapersen",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "3,4-Diaminopyridine (3,4-DAP)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Lambert-Eaton Myasthenic Syndrome (LEMS)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Double-blind placebo-controlled withdrawal study",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular transmission enhancement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Potassium channel blocker",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Acetylcholine release improvement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Triple Timed Up & Go (3TUG) test",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Amifampridine (Firdapse)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Myasthenia Gravis",
                "count": 1,
                "cluster": "Chronic Inflammatory and Autoimmune Neuromuscular Disorders"
            },
            {
                "topic": "Pyridostigmine",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Immunomodulatory therapies for LEMS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Small-cell lung cancer (SCLC) association with LEMS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Autoimmune disruption of voltage-gated calcium channels",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody exclusion criteria in study",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical research locations in US academic centers",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Amgen Inc. biopharmaceutical company",
                "count": 4,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Amgen oncology and rare disease pipeline drugs",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "MariTide obesity drug development",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Xaluritamig immunotherapy for prostate cancer",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Amgen manufacturing and supply chain expansion",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Amgen acquisitions (Five Prime Therapeutics, Rodeo Therapeutics)",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "3,4-Diaminopyridine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Coenzyme Q10 supplementation in muscular dystrophies",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Lisinopril use in muscular dystrophies",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Becker Muscular Dystrophy (BMD)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Limb Girdle Muscular Dystrophy (LGMD)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Myocardial Performance Index (MPI) monitoring",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial design: factorial design with 4 arms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 and Phase 3 clinical trial stages",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Coenzyme Q10 antioxidant mechanism and ATP synthesis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA approval of gene therapy Elevidys for DMD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Coenzyme Q10 manufacturing companies and market players",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "Coenzyme Q10 oral formulations and dosing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exclusion criteria in muscular dystrophy trials (e.g., spine curvature >30%, ACE inhibitor hypersensitivity)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cardiac involvement in muscular dystrophies and ACE inhibitor therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gene mutations affecting dystrophin and sarcoglycans in muscular dystrophies",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Physical therapy and orthopedic interventions in muscular dystrophies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Investigational treatments: utrophin upregulation and myostatin inhibition",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Randomized allocation without masking in clinical trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial sites for muscular dystrophy research (multiple international centers)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Coenzyme Q10 off-label uses (e.g., Parkinson's, statin myopathy)",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Coenzyme Q10",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Losmapimod (GW856553) p38 MAPK inhibitor",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain from peripheral nerve injury",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 randomized double-blind clinical trial NCT00969059",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "p38 MAPK pathway role in neuropathic pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Losmapimod dosing 7.5 mg BID oral film-coated tablet",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pain intensity numerical rating scale (PI-NRS) outcome measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral nerve injury and neuralgia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "GlaxoSmithKline (GSK) sponsorship and drug development",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial completed July 2010 with 168 subjects",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Safety and efficacy evaluation of losmapimod in neuropathic pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "COPD and acute coronary syndrome indications for losmapimod",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism: Inhibition of pro-inflammatory cytokines via p38 MAPK",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain epidemiology and risk factors (diabetes, nerve injury)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain symptoms: allodynia and hyperalgesia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Study locations: Australia, Denmark, Norway, Russia, Spain, UK",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmacological therapies for neuropathic pain (e.g., TENS)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Alternative treatments: acupuncture, biofeedback, mindfulness",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial secondary outcomes: dynamic allodynia, McGill Pain Questionnaire",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "GSK corporate profile and recent acquisitions",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Losmapimod",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Escitalopram",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Polyneuropathy",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain Treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Selective Serotonin Reuptake Inhibitor (SSRI)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Double-Blind Placebo-Controlled Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pain Relief Outcome",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "H. Lundbeck A/S",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT00162968",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Antidepressants for Neuropathic Pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Polyneuropathy Symptoms and Pathophysiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Polyneuropathy Epidemiology and Risk Factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Polyneuropathy Treatment Options",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Manufacturing in Denmark, France, Italy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Lundbeck Acquisition of Longboard Pharmaceuticals",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Escitalopram",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Salbutamol (albuterol) oral tablet",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Placebo oral capsule",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Myasthenia Gravis (MG)",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "Muscle weakness as MG symptom",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Beta-agonist therapy for Myasthenia Gravis",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT03914638",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Randomized crossover clinical trial design",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Double masking in clinical trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 and Phase 3 clinical trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "MG Quality of Life 15-items (MG-QOL15) outcome measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "MG Activities of Daily Living (MG-ADL) outcome measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuro-QoL fatigue assessment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Quantitative Myasthenia Gravis (QMG) score",
                "count": 2,
                "cluster": "Nipocalimab and Complement Inhibition in Myasthenia Gravis"
            },
            {
                "topic": "Myasthenia Gravis Composite (MG-Composite) score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse event monitoring in MG clinical trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "University of Aarhus clinical research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Jan Lykke Scheel Thomsen MD, PhD Fellow",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Adult patients with generalized myasthenia gravis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exclusion criteria in MG studies (malignancy, thymectomy, MG crisis)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Department of Neurology, Aalborg University Hospital",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Neurology, Aarhus University Hospital",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Salbutamol drug class: short-acting \u03b22 adrenergic receptor agonist (SABA)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Salbutamol pharmacologic mechanism - \u03b22 receptor activation and bronchodilation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Approved uses of Salbutamol for asthma and COPD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label use of Salbutamol for hyperkalemia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Salbutamol drug formulations (inhaler, nebulizer, oral tablets, IV)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Salbutamol regulatory approval (FDA, EMA, MHRA)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Salbutamol patent history and generic availability",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "GlaxoSmithKline (GSK) pharmaceutical company overview",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "GSK therapeutic focus areas including asthma and respiratory diseases",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "GSK R&D pipeline and investment in novel medicines",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "GSK collaborations and strategic partnerships (e.g. ViiV Healthcare)",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Myasthenia Gravis epidemiology and prevalence data",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "MG pathophysiology involving antibodies against acetylcholine receptors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "MG standard treatments: acetylcholinesterase inhibitors, immunosuppressants",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "MG alternative therapies: plasmapheresis, IVIG, thymectomy, beta-agonists",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical MG management: physical therapy, lifestyle adjustments",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Research on beta-agonists improving neuromuscular transmission in MG",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Salbutamol",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Acoramidis",
                "count": 17,
                "cluster": "Other"
            },
            {
                "topic": "Transthyretin Amyloidosis (ATTR)",
                "count": 14,
                "cluster": "Other"
            },
            {
                "topic": "ATTR-CM (Transthyretin Amyloid Cardiomyopathy)",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "ATTR-PN (Transthyretin Amyloid Polyneuropathy)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "TTR Stabilizer Drugs",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 Clinical Trials",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Eidos Therapeutics",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "BridgeBio Pharma",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "ATTRibute-CM Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gene Silencing Agents for ATTR",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tafamidis (TTR Stabilizer)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Patisiran and Inotersen",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Amyloidogenesis Suppressant Drug Class",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Oral Dosage Form of Acoramidis",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "FDA Approval of Acoramidis (2024)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "European Medicines Agency (EMA) Marketing Authorization Application for Acoramidis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic Variants of TTR (e.g. V122I)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Heart Failure due to Amyloid Deposits",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathy from Amyloid Deposits",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, Double-Blind, Placebo-Controlled Study Design",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Quadruple Masking Clinical Trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Stanford University Clinical Site",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Yale University School of Medicine Clinical Site",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mayo Clinic Clinical Sites",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Other US and European Clinical Trial Sites",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "BridgeBio Pharma's R&D Pipeline Drugs",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Infigratinib (FGFR1-3 Inhibitor)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Encaleret for Hypocalcemia Type 1",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "BBP-418 for Limb-Girdle Muscular Dystrophy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "BridgeBio Pharma Commercial Strategy and Partnerships",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Acquisition of Eidos Therapeutics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cardiomyopathy Treatment in Genetic Diseases Context",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Acoramidis",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "MASCT-I biological intervention",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Doxorubicin chemotherapy drug",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Ifosfamide chemotherapy drug",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Soft Tissue Sarcoma treatment",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Leiomyosarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Liposarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Synovial Sarcoma",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Angiosarcoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Undifferentiated Pleomorphic Sarcoma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Epithelioid Sarcoma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Malignant Peripheral Nerve Sheath Tumors",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibrosarcoma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pleomorphic Rhabdomyosarcoma",
                "count": 1,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Endometrial Stromal Sarcoma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 3,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Randomized Phase II clinical trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Progression-Free Survival outcome",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Overall Survival outcome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Objective Response Rate outcome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Disease Control Rate outcome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Adverse events in chemotherapy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Sun Yat-sen University Cancer Center Guangzhou",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Doxil liposomal formulation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sun Pharmaceutical Myocet liposomal formulation",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Teva Pharmaceutical generic doxorubicin",
                "count": 3,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Anthracycline antibiotic drug class",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "DNA intercalation by doxorubicin",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Topoisomerase II inhibition mechanism",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Free radical generation toxicity",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Doxorubicin approved cancer indications",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Liposomal doxorubicin formulations",
                "count": 2,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Chemotherapy cardiotoxicity monitoring",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Soft Tissue Sarcoma epidemiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sarcoma surgical treatment",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Radiation therapy for sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Targeted therapy in sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Immunotherapy in sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Reconstructive surgery post sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Physical therapy following sarcoma treatment",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Genetic and molecular sarcoma research",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Personalized medicine in sarcoma",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            },
            {
                "topic": "Pharmaceutical manufacturers of doxorubicin",
                "count": 1,
                "cluster": "Oncology Drugs and Clinical Trials in Soft Tissue Sarcomas"
            }
        ],
        "drug_generic_name": "Doxorubicin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "L-Serine",
                "count": 18,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 21,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical Trial NCT03580616",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS Functional Rating Scale-Revised (ALSFRS-R)",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Pulmonary Forced Vital Capacity (FVC)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Brain Chemistry Labs",
                "count": 5,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Dartmouth-Hitchcock Medical Center",
                "count": 6,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Elijah W. Stommel",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase IIa Clinical Trial",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Dose Tolerability Based on Subject Reporting",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuroprotective effects of L-Serine",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Inhibition of BMAA neurotoxin",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Activation of Autophagic-Lysosomal System",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Riluzole",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Edaravone",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neurodegenerative diseases",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Motor Neuron Disease",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Protein misfolding in neurodegeneration",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Excitotoxicity in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Oxidative Stress in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mitochondrial Dysfunction in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Genetic mutations associated with ALS (SOD1, C9orf72, TARDBP)",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Gene Therapy for ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Stem Cell Therapy for ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Immunomodulation for neuroinflammation",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Exosome-Based Therapies",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Physical Therapy for ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Speech Therapy for ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Nutritional Support in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Respiratory Support in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Psychological Support in ALS",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "L-Serine as dietary supplement",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "L-Serine formulations (oral tablets, powder, injectable)",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical trial termination due to IRB noncompliance",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            }
        ],
        "drug_generic_name": "L-Serine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Opicinumab (BIIB033) monoclonal antibody",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Multiple Sclerosis (MS)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Acute Optic Neuritis (AON)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "LINGO-1 protein inhibition",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Remyelination therapy",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1 and Phase 2 clinical trials of Opicinumab",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Biogen's neurological disease drug development",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics and safety evaluation in healthy volunteers",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled trials (RENEW and SYNERGY)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neurological autoimmune demyelinating diseases",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous dosing regimen of Opicinumab",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Trial discontinuation due to efficacy failure (Opicinumab development halted)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Oligodendrocyte maturation and myelin repair mechanisms",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial endpoints: pharmacokinetics, adverse events, disability improvement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "High-dose corticosteroid treatment for AON",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Disease-modifying therapies (DMTs) for MS",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Biogen's acquisitions enhancing immunology and rare disease portfolios",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody drug class characteristics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Study demographics: ages 18-55, all sexes, BMI 18-32 kg/m\u00b2",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Neurological disease epidemiology and risk factors (genetic, environmental, smoking)",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Opicinumab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Eteplirsen",
                "count": 10,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 10,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon 51 skipping",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Antisense oligonucleotide therapy",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Intravenous infusion dosing",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sarepta Therapeutics, Inc.",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial NCT03218995",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Safety and tolerability outcomes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics (Cmax, Tmax, AUC)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "6-Minute Walk Test (6MWT) efficacy measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscular dystrophies\u2013Duchenne subtype",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mutation amenable to exon 51 skipping",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric male patients aged 6-48 months",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA accelerated approval of Eteplirsen",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "EMA refusal of Eteplirsen approval",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gene therapy candidates SRP-9003 and SRP-9004",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Next-generation exon-skipping therapy SRP-5051",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Licensing partnership with Roche",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Manufacturing partnership with Catalent",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Limb-Girdle Muscular Dystrophies (LGMDs)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Muscle degeneration pathophysiology in DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Corticosteroid treatment in DMD (prednisone, deflazacort)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Physical and orthopedic supportive therapies in DMD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene therapy and exon skipping as disease-modifying approaches",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Dystrophin protein deficiency and restoration mechanisms",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Eteplirsen",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tafamidis meglumine",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Familial Amyloid Polyneuropathy (FAP)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Transthyretin (TTR) stabilization",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT00409175",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathy Impairment Score - Lower Limb (NIS-LL)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Inc.",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "FoldRx Pharmaceuticals, Inc.",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "TTR gene mutations",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Transthyretin amyloid cardiomyopathy (ATTR-CM)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Liver transplantation for FAP",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene silencing therapy - Patisiran",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene editing therapies (CRISPR) for FAP",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Amyloid fibril deposition in peripheral nerves",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Autosomal dominant inheritance of FAP",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2/3 randomized, double-blind, placebo-controlled trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oral capsule administration (20 mg daily)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled clinical trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rare disease therapeutic research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Multinational clinical trial sites for FAP",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Tafamidis meglumine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Everolimus",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Neurofibromatosis Type 1 (NF1)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Cutaneous Neurofibroma Lesions",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "mTOR Inhibitor Mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT02332902",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Mary Kay Koenig, MD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "The University of Texas Health Science Center at Houston",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Novartis AG",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 Interventional Study",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "3D Photographic Measurement of Lesion Volume",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse Events Grade 3-4",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Disfiguring Cutaneous Lesions in NF1",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Everolimus Brand Names (Afinitor, Zortress, Certican, Votubia)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Everolimus Approved Indications",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Genetic Mutation in NF1 gene",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Loss of Neurofibromin Tumor Suppressor Function",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ras and mTOR Signaling Pathways in NF1",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Selumetinib for Plexiform Neurofibromas",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Oncology and Immunology Therapeutic Focus",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Acquisition of Chinook Therapeutics",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Novartis R&D Pipeline and Revenue",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Everolimus",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Transdermal Magnesium Supplementation",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Cramps Treatment in Dialysis Patients",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Kidney Disease (CKD)",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "End Stage Renal Disease (ESRD)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Dialysis Related Complications",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Magnesium Chloride as Mineral Supplement",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Placebo-Controlled Clinical Trial NCT03082625",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Serum Magnesium Levels Measurement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral Neuropathy in Chronic Kidney Disease",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia Treatment with Transdermal Magnesium",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "BetterYou Magnesium Products",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Dr. Carolyn Dean Transdermal Magnesium Cream",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Magnesium Deficiency Management",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Magnesium Absorption Through Skin (Transdermal Delivery)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological Interventions in CKD (ACE inhibitors, Diuretics, etc.)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Dialysate Magnesium Concentration Research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Outcome Measures for Muscle Cramps (frequency, duration, severity)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility Criteria in CKD Clinical Trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Controlled Trials on Magnesium",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Patient Demographics in CKD Studies (age, sex)",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Magnesium chloride",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Gabapentin",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "Fabry Disease",
                "count": 10,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain",
                "count": 8,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Clinical Trial NCT01588314",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Placebo Controlled Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Small Fiber Neuropathic Pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "University of Minnesota",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Jeanine R. Jarnes, PharmD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genzyme, a Sanofi Company",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Enzyme Replacement Therapy (Agalsidase beta)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain Management in Fabry Disease",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Carbamazepine",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phenytoin",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentinoid Drug Class",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin Formulations (immediate and extended-release)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "FDA Approval for Gabapentin",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Inc.",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neurology Therapeutic Area",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin Mechanism of Action (\u03b12\u03b4 subunit binding)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin Indications",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Off-Label Uses of Gabapentin",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fabry Disease Pathophysiology (\u03b1-galactosidase A deficiency)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Lysosomal Storage Disorder",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic and Metabolic Disease Category",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fabry Disease Epidemiology and Prevalence",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fabry Disease Symptoms (neuropathic pain, angiokeratomas)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fabry Disease Treatment Challenges",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin Clinical Efficacy for Neuropathic Pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gabapentin Market and Patents",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Manufacturing Network",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Mergers and Acquisitions (Seagen acquisition)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Commercial Strategy and Partnerships",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Gabapentin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Inclusion Body Myositis (IBM)",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "Arimoclomol",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "Phase II Clinical Trial of Arimoclomol in IBM",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Niemann-Pick Disease Type C (NPC) Treatment with Arimoclomol",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Heat Shock Protein Activation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Zevra Therapeutics",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Inflammation and Atrophy in IBM",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, Double-Blind, Placebo-Controlled Study Design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inclusion Body Myositis Functional Rating Scale (IBMFRS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Disease",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Orphan Medicinal Product Designation for Arimoclomol",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Outcome Measures (Grip Strength, mTUG, MMT)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA Approval of Arimoclomol for NPC",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Heat Shock Protein Activators Drug Class",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rare Disease Therapeutics Development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Idiopathic Inflammatory Myopathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Protein Misfolding and Aggregation in Neuromuscular Disease",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "University of Kansas Medical Center",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "University College London Research Collaboration",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Orphazyme A/S",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Patent and Exclusivity Status of Arimoclomol",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical and Occupational Therapy for IBM",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Immunosuppressive Therapy Ineffectiveness in IBM",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous Immunoglobulin (IVIG) Therapy Trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gene and Stem Cell Therapy Research for IBM",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics and Dosage of Arimoclomol",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Arimoclomol Brand Name Miplyffa",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Zevra Therapeutics Revenue and Financials 2024",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT02753530",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Center and University Hospital Research Sites",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Controlled Trials in Rare Neuromuscular Disorders",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Molecular Pathogenesis of IBM",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Mitochondrial Dysfunction in IBM",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Use of Assistive Devices for IBM Patients",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Rare Disease Priority Review Voucher (PRV) Sale by Zevra",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Acquisition of Acer Therapeutics by Zevra",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pipeline Drugs KP1077 and Celiprolol",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Market Capitalization and Stock Information for Zevra",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Arimoclomol",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "[18F]FTC-146 radiotracer",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "sigma-1 receptor imaging",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "pediatric chronic pain diagnosis",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "PET/MRI imaging",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "chronic pain",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "neuropathic pain",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "nociceptive pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "neuralgia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "radiopharmaceutical development",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Stanford University research",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "GE HealthCare pharmaceutical diagnostics",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "clinical trial NCT04435821",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "pain management therapies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "sigma-1 receptor antagonists",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "radioligand biodistribution measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "chronic pain epidemiology in pediatrics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "neurological pain modulation pathways",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "non-invasive receptor quantification",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "investigational drug safety and efficacy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "medical imaging manufacturing in France",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "medical imaging manufacturing in India",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "clinical study enrollment criteria for pain",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "[18F]FTC-146",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Mexiletine",
                "count": 15,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Sporadic Amyotrophic Lateral Sclerosis (SALS)",
                "count": 7,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 9,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Motor Neuron Disease",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Cardiac arrhythmias",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuropathic pain",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase 2 Clinical Trial NCT01849770",
                "count": 6,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine dosage 300 mg",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine dosage 900 mg",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Placebo comparator in ALS trial",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS Functional Rating Scale-Revised (ALSFRS-R)",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Slow vital capacity measurement",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "University of Washington clinical research",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine mechanism - sodium channel blocker",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine brand names Mexitil and NaMuscla",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine approval for ventricular arrhythmias",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine off-label use for diabetic neuropathy",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Genetic mutations in ALS: SOD1, C9orf72, TARDBP, FUS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuroinflammation in ALS pathophysiology",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Oxidative stress in ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mitochondrial dysfunction in ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Excitotoxicity in ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "FDA approved ALS treatments: Riluzole and Edaravone",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Sodium Phenylbutyrate/Taurursodiol combination therapy",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Gene-silencing therapies for ALS (e.g., Tofersen)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Physical, Occupational, Speech, Nutritional, Respiratory therapies in ALS",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine pharmacokinetics (peak plasma concentration, AUC)",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical trial adverse effects and discontinuation rates",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine manufacturers: Camber Pharmaceuticals",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine manufacturers: Midas Pharma GmbH",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine manufacturers: Lupin Limited",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine manufacturers: Senores Pharmaceuticals, Inc.",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mexiletine manufacturers: Taj Pharmaceuticals Ltd.",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Orphan Drug Designation for mexiletine in myotonic disorders",
                "count": 1,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            }
        ],
        "drug_generic_name": "Mexiletine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Topiramate",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Sciatica",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Lumbar Radiculopathy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Low Back Pain",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsant Mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT00011804",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Topiramate for Sciatica Treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Topiramate Side Effects",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Topiramate Indications",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Topiramate Formulations",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Diphenhydramine as Active Placebo",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "NSAIDs for Sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical Therapy for Sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Epidural Steroid Injection",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Surgical Intervention for Sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Companies Marketing Topiramate",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "McNeil Pharmaceuticals (Kenvue)",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Janssen Pharmaceuticals",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Teva Pharmaceuticals",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mylan Pharmaceuticals (Viatris)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Off-label Uses of Topiramate",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurological Pain Conditions",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mechanisms of Topiramate Action",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Epidemiology of Sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Research on Anticonvulsants for Sciatica",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Double-Blind Crossover Trials",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Topiramate",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Vesleteplirsen (SRP-5051)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 9,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon 51 Skipping Therapy",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 Clinical Trial NCT04004065",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Safety Concerns: Hypomagnesemia and Kidney Function Decline",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sarepta Therapeutics, Inc.",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Antisense Oligonucleotide Therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous Infusion Drug Delivery",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Dystrophin Protein Level Measurement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics of Vesleteplirsen",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscular Dystrophy and Becker Muscular Dystrophy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene Therapy for DMD (Elevidys)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exondys 51 (Eteplirsen) Treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Dose Escalation and Expansion",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "DMD Gene Mutations and Pathophysiology",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Precision Genetic Medicine for Rare Diseases",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Global Clinical Trial Sites for DMD Studies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sarepta's Pipeline: SRP-9003 and SRP-9004 for LGMD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Strategic Collaborations: Roche and Catalent",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Degeneration and Weakness in DMD",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Vesleteplirsen",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Lenalidomide treatment regimen for MGUS-associated neuropathy",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Neuropathy associated with Monoclonal Gammopathy of Undetermined Significance (MGUS)",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Phase II clinical trial NCT00665652 on lenalidomide for MGUS neuropathy",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Peripheral nervous system diseases related to MGUS",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Lenalidomide pharmacology and mechanism of action",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Lenalidomide approved indications: multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Immunomodulatory therapies in MGUS neuropathy management",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Rituximab use in IgM MGUS-associated neuropathy",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Bruton tyrosine kinase inhibitors (e.g., ibrutinib) for MGUS neuropathy under investigation",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Clinical trial termination due to slow enrollment in MGUS neuropathy study",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Celgene Corporation development and Bristol-Myers Squibb acquisition of lenalidomide",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Bristol Myers Squibb corporate profile and oncology focus including lenalidomide portfolio",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Clinical outcomes and maintenance therapy studies with lenalidomide in multiple myeloma",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Disease epidemiology and pathophysiology of MGUS-associated neuropathy",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Non-pharmaceutical management of MGUS neuropathy: physical therapy and underlying condition control",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            }
        ],
        "drug_generic_name": "Lenalidomide",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Diphencyprone (DPCP) topical immunomodulator",
                "count": 12,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Cutaneous Neurofibromas treatment",
                "count": 7,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Neurofibromatosis type 1 (NF1)",
                "count": 8,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Phase I clinical trial for DPCP in cNF",
                "count": 4,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Topical immunotherapy for dermatological conditions",
                "count": 5,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Alopecia areata treatment with DPCP",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Warts treatment with DPCP",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Mechanism of action of DPCP as hapten-induced delayed hypersensitivity",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Icahn School of Medicine at Mount Sinai research",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Surgical excision and laser therapy for cutaneous neurofibromas",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "DPCP investigational status and lack of regulatory approval",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Clinical trial adverse event and tolerability assessment",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Genetic mutations in NF1 gene causing neurofibromas",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Psychosocial support for cutaneous neurofibroma patients",
                "count": 1,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "RXi Pharmaceuticals licensing of DPCP formulation",
                "count": 1,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            }
        ],
        "drug_generic_name": "Diphenylcyclopropenone (DPCP)",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Papaverine Hydrochloride",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Radial Artery Spasm",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Transradial Cerebral Angiography",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Controlled Trial NCT05861765",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Vasodilators",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Injection Administration via Radial Artery Sheath",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Design Phase 2b",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain Intensity Measurement in Right Forearm",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Transradial Approach Failure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sun Yat-sen Memorial Hospital",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Yamei Tang Principal Investigator",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral Vascular Diseases",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Cramp",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Merck & Co Pharmaceutical Manufacturer",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phosphodiesterase Inhibition Mechanism",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cerebral and Coronary Vasospasms Treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Erectile Dysfunction Intracavernosal Therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cryopreservation of Blood Vessels with Vasodilator",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Recruitment Status",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Intra-arterial Nitroglycerin and Verapamil Therapy for RAS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mechanical Prevention Methods for Radial Artery Spasm",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Modified Allen Test as Exclusion Criteria",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Interventional Quadruple-masked Parallel-group Study",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Demographic Risk Factors for Radial Artery Spasm",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Hydrophilic-coated Sheaths to Reduce Spasm Incidence",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Papaverine Hydrochloride",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Bocidelpar (ASP0367)",
                "count": 14,
                "cluster": "Other"
            },
            {
                "topic": "Primary Mitochondrial Myopathy (PMM)",
                "count": 15,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial myopathies",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Peroxisome Proliferator-Activated Receptor Delta (PPAR-\u03b4) modulation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne muscular dystrophy (DMD)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trials phase 1 and 2 of Bocidelpar",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Treatment efficacy and safety assessment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled trial design",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Muscular diseases",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Astellas Pharma Inc.",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Gene mutations affecting mitochondrial respiratory chain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial biogenesis enhancement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial dysfunction and energy metabolism",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Oral administration of investigational drugs",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Exercise and physical therapy for mitochondrial disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Coenzyme Q10 supplementation in mitochondrial disorders",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial termination due to efficacy failure",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Multicenter clinical trial sites in US medical centers",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic inheritance and epidemiology of PMM",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical R&D and mergers & acquisitions",
                "count": 4,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Bocidelpar",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Suzetrigine (SUZ)",
                "count": 9,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Diabetic Peripheral Neuropathic Pain (DPNP)",
                "count": 7,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Non-opioid analgesic",
                "count": 4,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "NaV1.8 sodium channel blocker",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Phase 3 clinical trial of Suzetrigine",
                "count": 3,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Pain management in diabetic neuropathy",
                "count": 5,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Vertex Pharmaceuticals Incorporated",
                "count": 6,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Clinical trial NCT06696443",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Diabetic neuropathy treatment",
                "count": 4,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Acute pain treatment approval for Suzetrigine",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Painful lumbosacral radiculopathy clinical trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Safety and tolerability outcomes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "SF-36v2 Physical Component Summary (PCS) Score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Short form McGill Pain Questionnaire-2 (SF-MPQ-2) Total Score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral nerve disorders",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Antiepileptic drugs for neuropathic pain",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Gabapentin and Pregabalin",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Duloxetine for neuropathic pain",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Tricyclic antidepressants (TCAs)",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Capsaicin cream 8% patch for DPNP",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Transcutaneous electrical nerve stimulation (TENS)",
                "count": 1,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Alpha-lipoic acid for neuropathic pain",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Gene therapy and regenerative medicine for neuropathy",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Vertex\u2019s cystic fibrosis treatment TRIKAFTA/KAFTRIO",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Vertex\u2019s gene-edited cell therapy CASGEVY",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Vertex\u2019s CFTR modulator ALYFTREK",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Vertex acquisition of Alpine Immune Sciences",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Clinical research sites for Suzetrigine trial in USA",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            }
        ],
        "drug_generic_name": "Suzetrigine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Kybella (deoxycholic acid) injection for cutaneous neurofibromas",
                "count": 6,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Asclera (polidocanol) injection for cutaneous neurofibromas",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "755nm Alexandrite laser treatment for cutaneous neurofibromas",
                "count": 4,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "1064nm Nd:YAG laser treatment for cutaneous neurofibromas",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Cutaneous neurofibromas (cNFs) treatment and management",
                "count": 7,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Neurofibromatosis Type 1 (NF1) disease and genetics",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT06300502 for cNFs therapies",
                "count": 5,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "MEK inhibitors (e.g., Selumetinib) for cutaneous neurofibromas",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Topical MEK inhibitor NFX-179 for cNFs",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Surgical removal of cutaneous neurofibromas",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Radiofrequency ablation for cutaneous neurofibromas",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Skin cooling during laser treatment to reduce pain in cNFs therapy",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Gene therapy approaches targeting NF1 mutations",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Immunotherapy for neurofibroma treatment",
                "count": 2,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Massachusetts General Hospital research on cNFs",
                "count": 3,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "AbbVie Inc. corporate profile and Kybella marketing",
                "count": 4,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Clinical outcome measures in cNFs trials (adverse events, patient satisfaction, quality of life)",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Deoxycholic acid",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Ataluren drug therapy",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 7,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Nonsense mutation read-through",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "PTC Therapeutics company",
                "count": 5,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Clinical trials of ataluren in DMD",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Phase 2a extension study NCT00759876",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Translarna brand",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Protein restoration therapy",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Muscle function improvement metrics",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Cystic fibrosis nonsense mutation treatment",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Gene therapy and exon skipping in DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Safety and efficacy of ataluren",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "PTC Therapeutics pipeline drugs (Sepiapterin, PTC518, Vatiquinone)",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "PTC Therapeutics commercial strategy and partnerships",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Muscular dystrophy epidemiology and pathophysiology",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Adverse events in ataluren trials",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "DMD respiratory and cardiac management",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Dystrophin protein restoration",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Pharmacological management with corticosteroids in DMD",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Drug formulation as oral powder mixed with milk",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            }
        ],
        "drug_generic_name": "Ataluren",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Idebenone",
                "count": 7,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 7,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "SIDEROS Study",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Respiratory function assessment in DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Gene therapy for Duchenne Muscular Dystrophy",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon skipping therapies for DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Santhera Pharmaceuticals",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Leber's Hereditary Optic Neuropathy (LHON) treatment with Idebenone",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Friedreich's Ataxia and Idebenone",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular diseases research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial termination due to futility",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial function enhancement by Idebenone",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oxidative stress and antioxidant therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adverse events monitoring in Idebenone trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Drug dosing regimen of Idebenone (900 mg/day)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Multicenter clinical trials in US and Europe",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle degeneration pathophysiology in DMD",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "CRISPR/Cas9 gene editing research for DMD",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Cell-based therapies for muscular dystrophy",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            }
        ],
        "drug_generic_name": "Idebenone",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Vitamin D supplementation for painful diabetic neuropathy",
                "count": 6,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Vitamin D 5000 IU oral tablet",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Painful diabetic neuropathy treatment",
                "count": 4,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Standard therapy for painful diabetic neuropathy (gabapentin, pregabalin, amitriptyline)",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Randomized clinical trial NCT04689958",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Vitamin D mechanism in neuropathy (VDR binding and nerve regeneration)",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Vitamin D deficiency and diabetic neuropathy association",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Pain measurement scales in neuropathy trials (VAS, Numeric Pain Scale, Brief Pain Inventory)",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Eligibility criteria for vitamin D neuropathy trial (low vitamin D, adults with PDN)",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Bethesda Hospital Yogyakarta clinical trial site",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Pharmaceutical manufacturers of vitamin D supplements (Pfizer, Merck, Novartis)",
                "count": 3,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Neuropathic pain management adjunct therapies (TENS, acupuncture)",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Epidemiology and risk factors of painful diabetic neuropathy",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Vitamin D off-label use in diabetic neuropathy",
                "count": 2,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Novartis US manufacturing and R&D expansion",
                "count": 1,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            }
        ],
        "drug_generic_name": "Vitamin D",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "LY3556050 drug",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Peripheral Neuropathy (DPN)",
                "count": 8,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Phase 2 clinical trial NCT06074562",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Somatostatin Receptor Type 4 (SSTR4) agonist",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Peripheral Neuropathic Pain (DPNP)",
                "count": 4,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Pain intensity numeric rating scales (API-NRS, WPI-NRS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled randomized double-blind study",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eli Lilly and Company",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Principal Investigators for LY3556050 trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Oral drug administration",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Osteoarthritis (OA) pain clinical studies of LY3556050",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Low Back Pain (CLBP) clinical studies of LY3556050",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial recruitment and study design details",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for LY3556050 trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Adverse events from LY3556050 treatment",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic neuropathy pathophysiology mechanisms",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Pharmacological therapies for diabetic neuropathy",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Neuropathic pain management approaches",
                "count": 1,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Eli Lilly pharmaceutical manufacturing and global distribution",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Eli Lilly research pipeline drugs (Orforglipron, Retatrutide)",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            },
            {
                "topic": "Eli Lilly mergers and acquisitions (Versanis Bio, Point Biopharma)",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            }
        ],
        "drug_generic_name": "LY3556050",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Mirogabalin (DS-5565)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Pregabalin Comparator",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Peripheral Neuropathy (DPN)",
                "count": 7,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Neuropathic Pain Treatment",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 Clinical Trial NCT01496365",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Daiichi Sankyo Pharmaceutical Company",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "\u03b12\u03b4 Ligand Mechanism of Action",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain Associated Conditions",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Outcomes: Pain Score Reduction",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Adverse Events: Dizziness, Somnolence, Headache",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Design: Randomized, Double-Blind, Placebo-Controlled",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Drug Dosage Regimens for Mirogabalin",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Neuropathy Epidemiology and Risk Factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological Therapies for DPN",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-label Uses of Mirogabalin",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia Treatment Research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic Neuralgia Treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Daiichi Sankyo Oncology Pipeline",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Daiichi Sankyo Financial Overview and Manufacturing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsants for Neuropathic Pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Participant Demographics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Global Distribution and Licensing Partnerships",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Mirogabalin",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Bimagrumab (BYM338)",
                "count": 14,
                "cluster": "Other"
            },
            {
                "topic": "Sporadic Inclusion Body Myositis (sIBM)",
                "count": 17,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT01925209",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Strength and Mobility Assessment",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Activin Receptor Type II Inhibition",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal Antibody Drug Class",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Lean Body Mass Increase",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "6 Minute Walking Distance (6MWD) Test",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Quadriceps Quantitative Muscle Testing (QMT)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "sIBM Functional Assessment (sIFA) Score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Short Physical Performance Battery (SPPB) Score",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Wasting Disorders Treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Pharmaceuticals Clinical Research",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2b/3 Randomized, Double-blind, Placebo-controlled Study",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Disease Epidemiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inflammatory and Degenerative Muscle Pathophysiology",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Use of Placebo in Clinical Trials",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Dose-finding Studies for BYM338",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Hypertrophy and Fat Loss Mechanism",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sarcopenia Clinical Trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Obesity and Type 2 Diabetes Treatment Research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "No FDA Approval for Bimagrumab as of 2025",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Advanced Age as Risk Factor for sIBM",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Trial Outcome: No Significant Mobility Improvement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Assistive Device Use in sIBM Patients",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical and Occupational Therapy in sIBM",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Global Manufacturing and Distribution",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Novartis Strategic Acquisitions and Collaborations",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Bimagrumab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Brivaracetam drug dosing regimens",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Post-Herpetic Neuralgia (PHN) treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Brivaracetam clinical trial NCT00160667",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma clinical research in neurology",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Brivaracetam mechanism of action via SV2A binding",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 randomized placebo-controlled trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Brivaracetam adverse effects profile",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain measurement scales (e.g., SF-MPQ, VAS)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Antiepileptic drugs (AEDs) for seizure adjunctive therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Brivaracetam oral and intravenous formulations",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Brivaracetam regulatory approvals (FDA, EMA, MHRA, Health Canada)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "PHN epidemiology and risk factors (age, diabetes)",
                "count": 1,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "PHN non-pharmaceutical management approaches (physical therapy, CBT, TENS)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma business overview and market presence",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma manufacturing facilities in Belgium, Switzerland, Japan, China",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "UCB Pharma acquisitions: Ra Pharmaceuticals and Zogenix",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Brivaracetam",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "GNE Myopathy",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Hereditary Inclusion Body Myopathy (HIBM)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Sialic Acid Extended Release (SA-ER)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Aceneuramic Acid Extended Release (Ace-ER)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 Clinical Trial of SA-ER",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 Clinical Trial of Ace-ER",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sialic Acid Supplementation Therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Strength and Function Assessment in HIBM",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, Double-Blind, Placebo-Controlled Clinical Trial Design",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ultragenyx Pharmaceutical Inc.",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Gene Therapy Research for GNE Myopathy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Distal Myopathy with Rimmed Vacuoles (DMRV)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Nonaka Disease",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of Action of Ace-ER: Sialic Acid Biosynthesis Restoration",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Disorder Pathophysiology in GNE Myopathy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Eligibility Criteria for GNE Myopathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Geographic Sites of Clinical Trials (UCLA, Washington University, NYU, Hadassah Hospital)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rare and Ultra-rare Genetic Muscle Disorders",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sialylation Deficiency in Muscle Cells",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "No Approved Disease-modifying Therapy for GNE Myopathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Supportive Care in GNE Myopathy Management",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "GeneTx Biotherapeutics Acquisition by Ultragenyx",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Expanded Rare Disease Gene Therapy Pipeline at Ultragenyx",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Aceneuramic Acid Extended Release",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Duloxetine 60 mg daily dosage",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Treatment of Fibromyalgia with Duloxetine",
                "count": 5,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia disease characteristics and epidemiology",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "HIV-1 infection co-morbidity in fibromyalgia treatment study",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT00552682 for Duloxetine efficacy in fibromyalgia with HIV-1",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Duloxetine adverse effects and pharmacokinetic profile",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia management including antidepressants and anticonvulsants",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Central sensitization and neurotransmitter imbalance in fibromyalgia pathophysiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eli Lilly and Company pharmaceutical manufacturing and market strategy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Eli Lilly acquisitions in cardiometabolic and oncology sectors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eli Lilly partnership with Amazon Pharmacy for medication delivery",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Duloxetine approved indications including major depressive disorder and neuropathic pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Off-label uses of Duloxetine such as stress urinary incontinence and osteoarthritis",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Duloxetine formulation as delayed-release oral capsules",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical outcome measures: Brief Pain Inventory, SF-36, Beck Depression Inventory, POMS-A scores",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for Duloxetine clinical trial in fibromyalgia and HIV",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Duloxetine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Bedrocan-type cannabis (22% THC, <1% CBD)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Myofascial Pain Syndromes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain intensity Numerical Rating Scale (NRS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "San Carlo Hospital, Potenza, Italy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase 4 clinical trial NCT05939466",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Medical cannabis low dosage treatment for fibromyalgia pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Cannabinoid receptors CB1 and CB2 mechanism of action",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Standardized medicinal cannabis production",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology: central sensitization and neurotransmitter imbalance",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia comorbid conditions (e.g., rheumatoid arthritis, lupus)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia epidemiology and risk factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia treatment: analgesics, antidepressants, anticonvulsants, CBT, physical therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cannabis-based therapies for fibromyalgia pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Bedrocan International BV company and manufacturing overview",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Bedrocan clinical study six-month outcomes on pain and quality of life",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Medical cannabis decoction preparation and dosing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia symptom domains: pain, fatigue, cognitive difficulties",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Alternative fibromyalgia therapies: acupuncture, massage, yoga, Tai Chi",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia genetic and environmental factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Bedrocan re-entry and cultivation license in Canadian market",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Cannabis sativa L. 'Afina'",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "AJH-2947",
                "count": 16,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1 Clinical Trial",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain",
                "count": 6,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Diabetic Neuropathies",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Post-Herpetic Neuralgia",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "TRPV1 Receptor Antagonist",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "JMackem Co., Ltd",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics and Pharmacodynamics Evaluation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Single and Multiple Ascending Dose Study",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, Double-Blind, Placebo-Controlled Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Safety and Tolerability Assessment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Oral Tablet Formulation",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Seoul National University Hospital",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neurological Diseases",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain Management Drug Development",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Small Molecule Analgesics",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Pain Therapeutics",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial in Healthy Korean and Caucasian Males",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Adverse Events Monitoring in Trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "NCT06155487 Clinical Trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Patent Protection for New Molecular Entities",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Intractable Disease Drug Research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Drug Dosage Variations (100mg to 800mg)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Development in South Korea",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "AJH-2947",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "FV-100 antiviral nucleoside analogue",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Valacyclovir antiviral nucleoside analogue",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster (shingles) treatment",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic Neuralgia prevention",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "NCT02412917 Phase 3 clinical trial",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "ContraVir Pharmaceuticals / Hepion Pharmaceuticals",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Antiviral therapy dosing regimens",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Acute herpes zoster associated pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Varicella-Zoster Virus (VZV) inhibition mechanism",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 randomized double-blind comparative study",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical efficacy and safety outcomes in herpes zoster",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inhibitex Bristol-Myers Squibb drug development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster epidemiology and risk factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Herpes Zoster pathophysiology and viral latency",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antiviral drug pharmacokinetics FV-100",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Hepatitis B virus (HBV) antiviral drug pipeline",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-alcoholic steatohepatitis (NASH) drug development",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CMX157 tenofovir analog for HBV",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ciclofilin Pharmaceuticals acquisition by Hepion",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chimerix collaboration for antiviral development",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "FV-100",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Pentoxifylline dosing regimen",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pentoxifylline mechanism of action",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pentoxifylline clinical use in intermittent claudication",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pentoxifylline off-label uses",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy clinical trial NCT00102453",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy epidemiology",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy pathophysiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy treatment and management",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy genetic basis and inheritance",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle strength measurement in clinical trials (QMT and MMT)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cooperative International Neuromuscular Research Group (CINRG)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pentoxifylline pharmaceutical formulations and brands",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Steroid-naive Duchenne Muscular Dystrophy patients",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial design: open-label, single-group, non-randomized phases 1 and 2",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Locations of Duchenne Muscular Dystrophy clinical trial sites",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Use of corticosteroids and cardiac/respiratory care in DMD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Experimental therapies for Duchenne Muscular Dystrophy (gene therapy, exon skipping)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Manufacturing and marketing of generic pentoxifylline",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Pentoxifylline",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Milnacipran drug",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Myofascial Pain Syndromes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT01418651",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Milnacipran pharmacology (SSNRI mechanism)",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Milnacipran dosage and administration",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Milnacipran clinical trial results",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia treatment with antidepressants",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia non-pharmacological treatments",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia epidemiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Forest Laboratories company",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Actavis company",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Allergan company",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Milnacipran brand names and global approvals",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia clinical trial endpoints (pain severity)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Milnacipran adverse events (nausea, headache)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia risk factors (genetic, infection, stress)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia comorbidities (IBS, TMJ disorders, mood disorders)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            }
        ],
        "drug_generic_name": "Milnacipran",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Viltolarsen (NS-065/NCNP-01)",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "Duchenne Muscular Dystrophy (DMD)",
                "count": 11,
                "cluster": "Duchenne Muscular Dystrophy (DMD) and Muscular Dystrophies: Treatment and Gene Therapy"
            },
            {
                "topic": "Exon 53 Skipping Therapy",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous Infusion Dosage Levels (40 mg/kg, 80 mg/kg)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Dystrophin Protein Production",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase II Clinical Trial NCT02740972",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Antisense Oligonucleotide Drug Class",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "NS Pharma, Inc.",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Nippon Shinyaku Co., Ltd.",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, Quadruple-Masked Interventional Study Design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Strength and Mobility Assessments (6MWT, NSAA)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Inclusion Criteria: Boys aged 4 to <10 years with DMD amenable to exon 53 skipping",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroid Treatment in DMD (Prednisone, Deflazacort)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Physical Therapy and Assistive Devices for DMD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene Therapy Approaches for DMD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cell-Based Therapies for DMD (Deramiocel)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cooperative International Neuromuscular Research Group (CINRG)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA Approval of Viltepso\u00ae (Viltolarsen) for DMD",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Safety and Tolerability Outcomes Using CTCAE v4.0",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "24-Week Treatment Period in Clinical Trials",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Viltolarsen",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "GRT9906 oral prolonged-release tablet",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Primary fibromyalgia syndrome",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Myofascial Pain Syndromes",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 randomized crossover clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Analgesic efficacy and safety assessment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "11-point Numerical Rating Scale (NRS) for pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia Impact Questionnaire (FIQ)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tender Point Index (TPI)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal GmbH pharmaceutical company",
                "count": 6,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Pain management drug development",
                "count": 4,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Investigational drug without regulatory approval",
                "count": 3,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Clinical trial NCT03783910",
                "count": 4,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Pain assessment endpoints in fibromyalgia",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Pharmaceutical research in chronic musculoskeletal pain",
                "count": 3,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Inclusion and exclusion criteria in fibromyalgia trials",
                "count": 2,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Research facilities in US locations for clinical trials",
                "count": 1,
                "cluster": "Gr\u00fcnenthal Pharmaceutical Company and Pain Management Portfolio"
            },
            {
                "topic": "Standard medical treatments for fibromyalgia",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Alternative therapies for fibromyalgia pain",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Research on gut microbiome role in fibromyalgia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal\u2019s R&D pipeline including RTX and Qutenza\u2122",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal mergers and acquisitions (Valinor Pharma, Nebido\u2122)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gr\u00fcnenthal\u2019s strategic partnerships and licensing deals",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-opioid pain relief receptor agonists under development",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Glucocorticoid receptor modulator for rheumatoid arthritis",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "GRT9906",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Propranolol treatment for PTSD and fibromyalgia",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia Syndrome (FMS)",
                "count": 4,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Post-Traumatic Stress Disorder (PTSD)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Reconsolidation therapy in PTSD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT04950426",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia Impact Measurement Questionnaire (FIQ)",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Beta-adrenergic receptor antagonist (beta blocker)",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Off-label use of propranolol for PTSD and fibromyalgia",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Centre Hospitalier Henri Laborit",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Propranolol pharmacology and mechanism of action",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Propranolol manufacturers: AstraZeneca, Cipla, Sandoz, generics",
                "count": 2,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Fibromyalgia and PTSD comorbidity and epidemiology",
                "count": 3,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Treatment approaches for fibromyalgia (antidepressants, anticonvulsants, CBT)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Treatment approaches for PTSD (SSRIs, EMDR, trauma-focused CBT)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Exclusion criteria for propranolol clinical trial (psychotic disorders, pregnancy)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Study recruitment and participant demographics (age 18+, French speakers)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Fibromyalgia pathophysiology involving abnormal pain response",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "PTSD neurobiological changes (amygdala, hippocampus)",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Propranolol oral and intravenous formulations",
                "count": 1,
                "cluster": "Fibromyalgia: Clinical Trials and Therapeutics"
            },
            {
                "topic": "Pharmaceutical companies\u2019 strategic focus on propranolol and related products",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Propranolol",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Mecasermin rinfabate (SomatoKine, Iplex)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Myotonic Dystrophy Type 1 (DM1)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1/2 clinical trial of Mecasermin rinfabate in DM1",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Insmed Incorporated",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "University of Rochester clinical research",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Recombinant human insulin-like growth factor-I (rhIGF-I) complex",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Subcutaneous injection treatment regimen",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Muscular dystrophies and related neuromuscular disorders",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "IPLEX investigational therapy for DM1",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Escalating dose cohorts in clinical studies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Gene therapy and RNA-based experimental treatments for DM1",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Symptom management in DM1 (mexiletine, pacemaker, physical therapy)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Insmed\u2019s pulmonary disease-focused R&D pipeline",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacokinetics enhancement via IGFBP-3 complexation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA approval of mecasermin rinfabate for IGF-1 deficiency",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical endpoints: safety and tolerability in DM1 trials",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic pathophysiology of DM1 (CTG repeat expansion in DMPK gene)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Adverse effect reduction by rhIGFBP-3 binding",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Epidemiology of DM1 including prevalence and inheritance patterns",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical interventions for DM1 (lifestyle, diet)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Insmed partnership with PARI for Lamira device manufacturing",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Brensocatib for neutrophil-mediated pulmonary diseases",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Treprostinil Palmitil Inhalation Powder for pulmonary hypertension",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Dyne Therapeutics DYNE-101 FDA orphan drug designation for DM1",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Mecasermin rinfabate",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Acalabrutinib",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Rituximab",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Waldenstr\u00f6m Macroglobulinemia",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral Neuropathy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Bruton Tyrosine Kinase (BTK) Inhibitor",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT05065554",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase II Clinical Trial",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Dana-Farber Cancer Institute",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Massachusetts General Hospital",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anti-MAG Antibodies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "B-cell Malignancies",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ibrutinib",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mantle Cell Lymphoma (MCL)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Lymphocytic Leukemia (CLL)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Small Lymphocytic Lymphoma (SLL)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous Immunoglobulin (IVIG)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Immunosuppressive Therapies",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Physical Therapy for Peripheral Neuropathy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Occupational Therapy for Peripheral Neuropathy",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Acerta Pharma",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "AstraZeneca",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "B-cell Receptor Signaling",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Lymphoplasmacytic Lymphoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Distal Acquired Demyelinating Symmetric (DADS) Neuropathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal Antibody Therapy",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Acalabrutinib",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Facioscapulohumeral Muscular Dystrophy",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Albuterol",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Clinical Trial NCT00004685",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscular Dystrophy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Beta-2 Adrenergic Agonists",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Muscle Mass and Strength Improvement",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular Genetic Disorders",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "D4Z4 Repeat Contraction and DUX4 Gene Expression",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Physical Therapy and Exercise Management for FSHD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gene Therapy Research in FSHD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological Treatment Investigations in FSHD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Outcomes Measurement: Voluntary Isometric Contraction Testing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Urinary Creatinine Excretion and DEXA Scans for Muscle Mass",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Albuterol Drug Formulations and Usage",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Off-label Use of Albuterol for Hyperkalemia",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Manufacturers of Albuterol (GSK, Cipla, Perrigo, Generics)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Design: Double Masking and Randomized Allocation",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pilot Study of Albuterol in FSHD Patients",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Albuterol",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Ethosuximide",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Complex Regional Pain Syndrome (CRPS)",
                "count": 15,
                "cluster": "Other"
            },
            {
                "topic": "Reflex Sympathetic Dystrophy (RSD)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized Controlled Trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 Clinical Trial",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Maximum Tolerated Dose (MTD)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain Intensity Scales (VAS and NRS)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain Symptom Inventory (NPSI)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Short Form 12v2 (SF-12v2)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsants for Neuropathic Pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-Controlled Parallel Group Study Design",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Quadruple Masking in Clinical Trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility Criteria for CRPS Clinical Trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Ethosuximide Pharmacology and Mechanism of Action",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "T-type Calcium Channel Blockade",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Absence Seizures Treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Oral Capsule and Suspension Formulations of Ethosuximide",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Off-Label Use of Ethosuximide in CRPS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CRPS Pathophysiology - Peripheral Sensitization",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "CRPS Pathophysiology - Central Sensitization",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Autonomic Nervous System Dysfunction in CRPS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CRPS Treatment Strategies - Physical and Occupational Therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CRPS Pharmacologic Treatments (NSAIDs, Anticonvulsants, Corticosteroids)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Interventional Therapies for CRPS (Nerve Blocks, Spinal Cord Stimulation)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-Pharmaceutical CRPS Therapies (Mirror Therapy, Graded Motor Imagery)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "CRPS Epidemiology and Risk Factors",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT00689585 on Ethosuximide for CRPS",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "McGill University Health Centre Clinical Research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Pharmaceutical Company Overview",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer CNS Drug Portfolio Shift",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Generic Drug Production of Ethosuximide",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Ethosuximide",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Salonsip plaster application protocol",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Sabi\u00e1 plaster application protocol",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Contusions (Bruises)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Sprains (Strains)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Myalgia (Muscle Pain)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Tendonitis (Tendon Inflammation)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Salonsip vs Sabi\u00e1 plaster clinical trial NCT00970658",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 randomized clinical trial design",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Topical analgesic patches for musculoskeletal injuries",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Methyl Salicylate Gel Patch active ingredients and mechanism",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Hisamitsu Pharmaceutical Company research and manufacturing",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Efficacy and safety outcome measures using Likert and visual analogue scales",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for musculoskeletal injury studies",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Musculoskeletal soft tissue injury treatment with topical patches",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial participant demographics: age 12+, all sexes",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Methyl Salicylate Gel Patch",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Pirfenidone",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Dermatomyositis Interstitial Lung Disease (Dm-ILD)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Idiopathic Pulmonary Fibrosis (IPF)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase III Randomized Clinical Trial NCT03857854",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Forced Vital Capacity (FVC) measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antifibrotic Therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Immunosuppressive Therapy for DM-ILD",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Anti-MDA5 Antibody associated ILD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Beijing Continent Pharmaceutical Co., Ltd.",
                "count": 4,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "GNI Group Ltd.",
                "count": 4,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Roche Products Pty Limited",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Pulmonary Rehabilitation in ILD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous Immunoglobulins (IVIG) in ILD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Plasma Exchange for severe ILD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Autoimmune-mediated Lung Fibrosis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Masking Methods (Quadruple masking)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fibrosis Biomarkers (SPP1) in DM-ILD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Genetic and Immunologic Factors in DM-ILD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Smoking Cessation in ILD management",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pirfenidone Patent Litigation",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Pirfenidone",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "AMZ002 injectable solution",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Vigabatrin",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Infantile Spasms",
                "count": 13,
                "cluster": "Other"
            },
            {
                "topic": "West Syndrome",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 clinical trial NCT05128344",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "AMZ002 vs Vigabatrin efficacy and safety",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, open-label, parallel intervention clinical trial design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "AMZ002 hormone replacement therapy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Infantile Spasms treatment in infants 2-24 months",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Infantile Spasms genetic factors (CDKL5, SCN2A, SCN8A, STXBP1)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Hypsarrhythmia EEG pattern",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroid hormonal therapy for IS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Adrenocorticotropic hormone (ACTH) therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketogenic diet for seizure control in IS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical intervention for brain lesions causing spasms",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Developmental support therapies for IS (physical, occupational, speech)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Tuberous sclerosis complex",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "AMZ002 investigational drug regulatory status and withdrawal",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Amzell B.V. pharmaceutical development company",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Amzell B.V. pipeline drugs: AMZ001, AMZ002, AMZ004",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Amzell B.V. acquisition of Bazell Pharma AG facility",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Amring Pharmaceuticals Inc. collaboration for AMZ002 development",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Vigabatrin use as active comparator in infantile spasms",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial geographic locations (US, Argentina, France, India, Italy, Mexico, Poland)",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "AMZ002",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "SYHA1402 oral tablets",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Dosages of SYHA1402 (25mg, 50mg, 100mg, 150mg)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Placebo-controlled clinical trials",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic Peripheral Neuropathy (DPN)",
                "count": 6,
                "cluster": "Topical Capsaicin and Neuropathic Pain Therapies"
            },
            {
                "topic": "Pharmacokinetics of SYHA1402",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Safety and tolerability of SYHA1402",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Food effect on drug absorption",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 1 clinical trial NCT04453618",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial NCT05116111",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Multiple dose administration of SYHA1402",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled study design",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for healthy adult volunteers (age 18-45, BMI 19-26)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurological complications of diabetes",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral nervous system diseases",
                "count": 2,
                "cluster": "Chemotherapy-Induced Peripheral Neuropathy and Pain Management Devices"
            },
            {
                "topic": "Drug development for diabetic peripheral neuropathy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial pharmacodynamics and efficacy endpoints",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of action under investigation for SYHA1402",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Investigational drug not yet approved by FDA, EMA, MHRA",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Chinese pharmaceutical industry and innovation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "CSPC Zhongqi Pharmaceutical Technology strategic partnerships and licensing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "CSPC Pharmaceutical Group global distribution and manufacturing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antidepressants and anticonvulsants in DPN management",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical therapies for diabetic neuropathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Epidemiology and risk factors for diabetic peripheral neuropathy",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial outcomes measuring Cmax, AUC, Tmax",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuromuscular diseases relevance (low)",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "SYHA1402",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Sonlicromanol (KH176)",
                "count": 8,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Primary mitochondrial diseases (PMD)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Maternally Inherited Diabetes and Deafness (MIDD)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 clinical trial of Sonlicromanol",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Khondrion BV",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Redox modulation and anti-inflammatory mechanism",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Fatigue and physical performance endpoints",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Genetic mitochondrial diseases",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Investigational oral drug formulation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2b clinical trial results for Sonlicromanol",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurological and muscular symptoms of mitochondrial diseases",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Antioxidant activity via thioredoxin/peroxiredoxin system",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Inhibition of microsomal prostaglandin E synthase-1 (mPGES-1)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Leigh's Disease",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Leber's Hereditary Optic Neuropathy (LHON)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Post-viral fatigue syndromes related to mitochondrial dysfunction",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Gene therapy approaches for mitochondrial DNA mutations",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mitochondrial biogenesis enhancement strategies",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT06451757 (KHENERFIN Study)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled trial design",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Quadrupole masking in clinical trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "United Mitochondrial Disease Foundation (UMDF) investment",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Sonlicromanol",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tazemetostat",
                "count": 13,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Epithelioid Sarcoma",
                "count": 11,
                "cluster": "Other"
            },
            {
                "topic": "Expanded Access Program",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Spindle Cell Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Sinonasal Carcinoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Small Cell Carcinoma of Ovary Hypercalcemic Type",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Thoracic Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Poorly Differentiated Chordoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "ATRT",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Malignant Rhabdoid Tumor",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Myxoid Spindle Cell Sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Epithelioid Malignant Peripheral Nerve Sheath Tumor",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Chondrosarcoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Renal Cell Carcinoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Myoepithelial Carcinoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Synovial Sarcoma",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Renal Medullary Carcinoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Malignant Mesothelioma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Desmoplastic Small Round Cell Tumor",
                "count": 2,
                "cluster": "Pediatric and Adolescent High-Risk Solid Tumors and Sarcomas"
            },
            {
                "topic": "Intramedullary Spinal Cord Schwannomatosis",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Follicular Lymphoma",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "EZH2 gene inhibition",
                "count": 3,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Histone-lysine methyltransferase inhibitor",
                "count": 2,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "PRC2 complex and gene silencing",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Oral histone methyltransferase inhibitor formulation",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "FDA accelerated approval for epithelioid sarcoma",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "FDA accelerated approval for follicular lymphoma",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Tazverik brand",
                "count": 1,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Loss of INI1/SMARCB1 in epithelioid sarcoma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "SWI/SNF chromatin remodeling complex dysfunction",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical resection for epithelioid sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Chemotherapy adjunct in epithelioid sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Radiotherapy for epithelioid sarcoma",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Epigenetic therapies for cancer",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Immune checkpoint inhibitors combination research",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trials NCT03874455 and NCT02601950",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Epizyme, Inc.",
                "count": 5,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "Ipsen acquisition of Epizyme",
                "count": 2,
                "cluster": "Miscellaneous Oncology and Pharmaceutical Topics"
            },
            {
                "topic": "EZM0414 SETD2 inhibitor",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "PRMT5 inhibitor development",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "PRMT1 inhibitor development",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Soft Tissue Sarcoma",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Tazemetostat",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "N-acetylcysteine",
                "count": 9,
                "cluster": "Other"
            },
            {
                "topic": "Cisplatin-induced toxicities",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Cisplatin nephrotoxicity",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Cisplatin ototoxicity",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Cisplatin-induced peripheral neuropathy",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Cancer chemotherapy with cisplatin",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial NCT06297369",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Audiometry assessment for ototoxicity",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Serum creatinine and blood urea nitrogen measurement",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral neuropathy assessment tools (CTCAE, FACT/GOG-Ntx, DN4)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Nephroprotective therapies for cisplatin toxicity",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Otoprotective therapies for cisplatin toxicity",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuroprotective agents for peripheral neuropathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Hydration protocols for cisplatin nephrotoxicity",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Amifostine as nephroprotectant",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Sodium thiosulfate as otoprotectant",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Intratympanic drug delivery for ototoxicity",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Genetic risk factors for cisplatin ototoxicity (GSTP1 variants)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Oncology and Nuclear Medicine department, Ain Shams University Hospitals",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical manufacturing of N-acetylcysteine",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical companies: Boehringer Ingelheim, Mylan, Teva, Fresenius Kabi, Sedico",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "N-acetylcysteine",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Trehalose intravenous infusion therapy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Oculopharyngeal Muscular Dystrophy (OPMD)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial of Trehalose for OPMD",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Seelos Therapeutics drug development pipeline",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Trehalose mechanism activating autophagy via TFEB",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Amyotrophic lateral sclerosis (ALS) treatment with Trehalose",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Gene silencing therapy for OPMD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Cell-based (myoblast transplantation) therapy for OPMD",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Surgical interventions for OPMD (Blepharoplasty, Cricopharyngeal myotomy)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Botulinum toxin injections for cricopharyngeal dysfunction",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Genetic mutations in PABPN1 causing OPMD",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Rare disease prevalence in French Canadians and Bukhara Jews",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial funding challenges leading to withdrawal",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled trial design with crossover",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Functional muscle and swallowing outcome measures in OPMD trials",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Supportive therapies for muscular dystrophy (physical therapy, assistive devices)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Seelos Therapeutics intranasal ketamine program for depression (SLS-002)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Seelos Therapeutics development of gene and peptide therapies for Parkinson's disease",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Seelos Therapeutics targeting spinocerebellar ataxia with Trehalose (SLS-005)",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Autophagy-targeted experimental therapies for neurodegeneration",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Trehalose",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Comboprofen oral solution",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Ibuprofen oral solution",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Magnesium oral solution",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Vitamin C oral solution",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Placebo oral solution",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Delayed Onset Muscle Soreness (DOMS)",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Muscle pain associated with DOMS",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for DOMS",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial NCT03223519",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Summed Pain Intensity Difference (SPID) outcome measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled study design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Spherium Biomed and Sant Pau Research Institute collaboration",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Musculoskeletal pain treatment research",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Use of antioxidants (Vitamin C) for muscle recovery",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Magnesium role in muscle cramp reduction",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain assessment during standing and sitting activities",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Male participants aged 18-45",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial completed in November 2017",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical DOMS therapies (massage, cryotherapy, compression garments)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of action of Comboprofen components",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Comboprofen",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "CNTX-4975 drug",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Morton's neuroma treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Trans-capsaicin analgesic",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Centrexion Therapeutics",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "TRPV1 receptor targeting",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Painful intermetatarsal neuroma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial NCT02678793",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Knee osteoarthritis pain",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Non-opioid chronic pain therapies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical study",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Sclerosing alcohol injections",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Radiofrequency ablation for neuroma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neurectomy surgery",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Cryogenic neuroablation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Metatarsal osteotomies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Footwear modifications for neuroma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Orthotic devices for neuroma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Corticosteroid injections for neuroma",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pain assessment scales (NPRS, PGIC)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FDA Fast Track designation for CNTX-4975",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "U.S. composition of matter patent for CNTX-4975",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial safety and tolerability endpoints",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Multi-center US clinical trial sites",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Chronic pain management pipeline drugs",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial analgesic efficacy endpoints",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Centrexion and Lilly strategic partnership",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic neuropathy pipeline drug CNTX-6016",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 knee osteoarthritis pain trial",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Trans-capsaicin",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Infliximab (TNF-alpha blocker)",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Postoperative Sciatica due to Lumbar Spinal Fibrosis",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "TNF-alpha inhibition treatment for postoperative sciatica",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 3 randomized double-blind placebo-controlled clinical trial NCT00385086",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Visual analogue scale (VAS) for pain assessment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Epidural fibrosis following lumbar spine surgery",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Biosimilars of infliximab (Inflectra, Renflexis, Avsola, Zymfentra)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Failed back surgery syndrome",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Epidural steroid injections for sciatica treatment",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Conservative management of postoperative sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Surgical discectomy and revision surgery for lumbar fibrosis",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Role of inflammatory cytokines, specifically TNF-alpha, in fibrosis formation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Eligibility criteria for infliximab clinical trial in postoperative sciatica",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial endpoints: 50% pain reduction at 10 days post-treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Principal Investigator Francois Rannou, Assistance Publique - H\u00f4pitaux de Paris",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Marketing and development companies of infliximab and biosimilars (Janssen Biotech, Pfizer, Amgen, Samsung Bioepis, Celltrion)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Monoclonal antibody biologic drugs targeting TNF-alpha",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Autoimmune diseases treated by infliximab (Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Formulation and dosing regimen of infliximab intravenous infusion",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Limitations and mixed evidence for TNF-alpha inhibitors in sciatica treatment",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical patent expiration and biosimilar development",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Infliximab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tauroursodeoxycholic Acid (TUDCA)",
                "count": 12,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 11,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neurodegenerative Diseases",
                "count": 5,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Motor Neuron Disease",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "TUDCA Clinical Trials in ALS",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Long-term Safety and Tolerability of TUDCA",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "TUDCA Mechanism of Action",
                "count": 3,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Gallstone Prevention by TUDCA",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Phase 3 Interventional Study NCT05753852",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "TUDCA Drug Formulation (250 mg Oral Capsules)",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "TUDCA Approval Status and Regulation",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Principal Investigators and Study Locations",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Riluzole and Edaravone as ALS Treatments",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Neuroprotection Mechanisms of TUDCA",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Clinical Trial Outcomes of TUDCA in ALS",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "TUDCA Manufacturers and Commercial Strategy",
                "count": 4,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Dr. Falk Pharma GmbH and Liver Disease Focus",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ICE Pharma and Liver Disease Therapeutics",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Grindeks Development of TUDCA for Neurodegenerative Diseases",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Wuhan Fuxing Biological Pharmaceutical and Traditional Medicine",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Mylan N.V. (Viatris) and TUDCA Distribution",
                "count": 2,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "ALS Pathophysiology and Genetics",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Supportive Therapies for ALS",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neuroprotective Agents and Experimental ALS Therapies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial Eligibility and Recruitment Criteria",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS Epidemiology and Risk Factors",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Tauroursodeoxycholic Acid (TUDCA)",
        "fit": true
    },
    {
        "result": [
            {
                "topic": "Eculizumab",
                "count": 10,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Generalized Myasthenia Gravis (gMG)",
                "count": 9,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Muscle Weakness",
                "count": 4,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Quantitative Myasthenia Gravis (QMG) Score",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Complement Protein C5 Inhibition",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Atypical Hemolytic Uremic Syndrome (aHUS)",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Immunosuppressive Therapies",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Phase 2 Clinical Trial NCT00727194",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Alexion Pharmaceuticals, Inc.",
                "count": 6,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Biosimilars of Eculizumab (Bkemv, Epysqli)",
                "count": 3,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Intravenous Infusion Formulation",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Crossover Randomized Controlled Trial Design",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Quantitative Myasthenia Gravis (QMG) Total Score Reduction",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Generalized Myasthenia Gravis Treatment Eligibility Criteria",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Thymoma and Thymectomy Exclusion Criteria",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Complement Inhibitors as Therapeutic Strategy",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Plasmapheresis and Plasma Exchange Exclusion",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Clinical Trial Quadruple Masking",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "US FDA Approval for Eculizumab Indications",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "European Medicines Agency Approval for Eculizumab",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "MHRA Approval for Eculizumab",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Alexion Pharmaceuticals Mergers and Acquisitions",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Biosimilar Manufacturing by Amgen Technology Ireland",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Biosimilar Manufacturing by Samsung Bioepis",
                "count": 2,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Neuromuscular Junction Autoimmune Pathophysiology",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Acetylcholine Receptor Antibody Positive Myasthenia Gravis",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Acetylcholinesterase Inhibitors in gMG",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Intravenous Immunoglobulin (IVIg) in gMG Management",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Quality of Life Measurement Using SF-36",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "MG-Activity of Daily Living Profile (MG-ADL)",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "MGFA Post-Intervention Status",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Physical Therapy as Adjunct Treatment",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Patent Exclusivity and Biosimilar Competition",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Rare Disease Therapeutic Focus at Alexion",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Recombinant Humanized Monoclonal Antibody Mechanism",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Eculizumab Market Names: Soliris, Bkemv, Epysqli",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            },
            {
                "topic": "Global Distribution Network of Eculizumab",
                "count": 1,
                "cluster": "Eculizumab and Complement Inhibitor Therapies in Autoimmune Disorders"
            }
        ],
        "drug_generic_name": "Eculizumab",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Thrombomodulin alfa (ART-123)",
                "count": 10,
                "cluster": "Other"
            },
            {
                "topic": "Chemotherapy-Induced Peripheral Neuropathy (CIPN)",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "Oxaliplatin-induced Peripheral Neuropathy (OIPN)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Disseminated Intravascular Coagulation (DIC) treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Veloxis Pharmaceuticals",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Asahi Kasei Pharma Corporation",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Intravenous infusion drug administration",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Phase 2 clinical trial of ART-123",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "FACT/GOG-NTX-12 neuropathy scale",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Randomized, double-blind, placebo-controlled trial design",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain management medications (Duloxetine, Gabapentin, Pregabalin)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neurotoxic chemotherapy agents (platinum compounds, taxanes, vinca alkaloids)",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Peripheral neuropathy epidemiology and risk factors",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial withdrawal due to design change",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Mechanism of action of thrombomodulin alfa",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Therapeutic focus on critical care and musculoskeletal disorders",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical mergers and acquisitions (Veloxis and Calliditas)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical CIPN management (physical therapy, acupuncture)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Patent and exclusivity status of recombinant proteins",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Use of recombinant human thrombomodulin in clinical research",
                "count": 3,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Thrombomodulin alfa",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Gabapentin enacarbil",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "ASP8825",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Painful diabetic polyneuropathy clinical trial NCT00508430",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic polyneuropathy",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic neuropathy",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Restless Legs Syndrome (RLS) treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Postherpetic neuralgia treatment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Astellas Pharma Inc.",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Quadruple masking randomized placebo-controlled study",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Oral extended-release formulation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic pain management",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Anticonvulsant drug class",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Diabetes mellitus complications",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Diabetic neuropathic pain epidemiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Clinical trial termination due to futility",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "FAAH inhibitors for neuropathic pain",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Polyneuropathy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Multiregional clinical trial in Japan",
                "count": 1,
                "cluster": "Other"
            },
            {
                "topic": "Pharmacological therapies for diabetic neuropathy",
                "count": 2,
                "cluster": "Neuropathic Pain Drug Development and Clinical Trials"
            }
        ],
        "drug_generic_name": "Gabapentin enacarbil",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Anti-MDA5 Antibody-Positive Dermatomyositis",
                "count": 12,
                "cluster": "Other"
            },
            {
                "topic": "JAK Inhibitors (Tofacitinib, Upadacitinib)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Prednisone (Corticosteroid treatment)",
                "count": 7,
                "cluster": "Other"
            },
            {
                "topic": "Clinical Trial NCT04966884 on JAK Inhibitors for Dermatomyositis",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Rapidly Progressive Interstitial Lung Disease (RP-ILD) in Dermatomyositis",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Total Improvement Score (TIS) Outcome Measure",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Glucocorticoids for Dermatomyositis Treatment",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Immunosuppressive Agents (Cyclophosphamide, Cyclosporine, Tacrolimus)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Plasma Exchange as Adjunctive Therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pulmonary Rehabilitation and Nutritional Support",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Type I Interferon Pathway in Dermatomyositis Pathophysiology",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "First Affiliated Hospital of Xi'an Jiaotong University Clinical Research",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Pharmaceutical Manufacturers of Prednisone (Teva, Sandoz, Amgen, Sun Pharma)",
                "count": 4,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Prednisone",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Selumetinib MEK1/2 inhibitor",
                "count": 6,
                "cluster": "Other"
            },
            {
                "topic": "Neurofibromatosis type 1 (NF1)",
                "count": 8,
                "cluster": "Cutaneous Neurofibromas and Neurofibromatosis Type 1 (NF1) Treatments"
            },
            {
                "topic": "Plexiform neurofibromas treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "MAPK/ERK signaling pathway inhibition",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Phase II clinical trial NCT06620354",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Objective Response Rate (ORR) endpoint",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Oral capsule drug formulation",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pediatric NF1 patients treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Merck & Co. Koselugo marketing",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Array BioPharma AstraZeneca development",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "RAS/MAPK pathway dysregulation in NF1",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Inoperable symptomatic neurofibromas",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "NF1 genetic mutation in NF1 gene",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "FDA and EMA approval for Selumetinib",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Clinical endpoints: duration of response and progression-free survival",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Non-pharmaceutical NF1 management strategies",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Surgical and laser therapies for neurofibromas",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Multikinase inhibitors drug class",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Merck & Co. oncology portfolio and manufacturing",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "AstraZeneca oncology R&D and acquisitions",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Selumetinib",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Ketamine Hydrochloride intravenous administration",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Cognitive Behavioral Therapy remote sessions",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Combination therapy Ketamine plus Cognitive Behavioral Therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Chronic Neuropathic Pain treatment",
                "count": 4,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain clinical trial NCT05639322",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine as NMDA receptor antagonist analgesic",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine use for anesthesia induction and maintenance",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine off-label use for treatment-resistant depression",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Psychotherapy for enhancing ketamine durability in neuropathic pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Phase 4 randomized controlled pilot trial design",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Patient-Reported Outcomes Measurement Information System PROMIS pain assessment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Inclusion criteria adults with moderate-to-severe chronic neuropathic pain",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Exclusion criteria psychiatric disorders and ketamine allergy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "St. Michael's Hospital Toronto clinical trial site",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer Inc pharmaceutical company",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Janssen Pharmaceuticals pharmaceutical company",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain epidemiology and prevalence",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain pathophysiology involving somatosensory system lesions",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain standard treatments antidepressants and anticonvulsants",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain alternative therapies botulinum toxin and cannabinoids",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Neuropathic Pain research neuromodulation and gene therapy",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine safety concerns abuse and cognitive impairment",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Esketamine intranasal formulation for depression",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Ketamine patent and generic availability",
                "count": 2,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Ketamine Hydrochloride",
        "fit": false
    },
    {
        "result": [
            {
                "topic": "Tofacitinib clinical trial for ALS",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Amyotrophic Lateral Sclerosis (ALS)",
                "count": 7,
                "cluster": "Amyotrophic Lateral Sclerosis (ALS) Therapeutics and Clinical Trials"
            },
            {
                "topic": "Janus Kinase (JAK) inhibitors",
                "count": 5,
                "cluster": "Other"
            },
            {
                "topic": "Neuroinflammation in ALS",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS disease epidemiology and pathology",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "ALS treatment and management",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "ALS clinical outcome measures (ALSFRS-R, Norris scale, ALSAQ-40)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer's Xeljanz (tofacitinib)",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Tofacitinib mechanism of action",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Neurological clinical trials design (early phase, single-group)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Beijing Tiantan Hospital ALS research",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "JAK-STAT signaling pathway modulation",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS genetic factors (C9orf72, SOD1)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS supportive therapies (physical, occupational, speech, respiratory)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "ALS research innovations (gene therapy, stem cells, immunomodulation)",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer company R&D and manufacturing overview",
                "count": 3,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer oncology and immunology pipeline drugs",
                "count": 2,
                "cluster": "Other"
            },
            {
                "topic": "Pfizer acquisition of Seagen for oncology portfolio",
                "count": 1,
                "cluster": "Other"
            }
        ],
        "drug_generic_name": "Tofacitinib",
        "fit": false
    }
]